Molecular Signatures of Obstructive Sleep Apnea in Adults: A Review and Perspective

Erna S. Arnardottir, MS[1,2,3]; Miroslaw Mackiewicz, PhD[1]; Thorarinn Gislason, MD, PhD[2,3]; Karen L. Teff, PhD[4,5]; Allan I. Pack, MBChB, PhD[1,3]

[1]Center for Sleep and Respiratory Neurobiology, Division of Sleep Medicine/Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; [2]Department of Respiratory Medicine and Sleep, Landspitali University Hospital, Reykjavik, Iceland; [3]Faculty of Medicine, University of Iceland, Reykjavik, Iceland; [4]Monell Chemical Senses Center, Philadelphia, PA; [5]Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania, Philadelphia, PA

The consequences of obstructive sleep apnea (OSA) are largely mediated by chronic intermittent hypoxia and sleep fragmentation. The primary molecular domains affected are sympathetic activity, oxidative stress and inflammation. Other affected domains include adipokines, adhesion molecules and molecules that respond to endoplasmic reticulum stress. Changes in molecular domains affected by OSA, assessed in blood and/or urine, can provide a molecular signature for OSA that could potentially be used diagnostically and to predict who is likely to develop different OSA-related comorbidities. High-throughput discovery strategies such as microarrays, assessing changes in gene expression in circulating blood cells, have the potential to find new candidates and pathways thereby expanding the molecular signatures for OSA. More research is needed to fully understand the pathophysiological significance of these molecular signatures and their relationship with OSA comorbidities.

Many OSA subjects are obese, and obesity is an independent risk factor for many comorbidities associated with OSA. Moreover, obesity affects the same molecular pathways as OSA. Thus, a challenge to establishing a molecular signature for OSA is to separate the effects of OSA from obesity. We propose that the optimal strategy is to evaluate the temporal changes in relevant molecular pathways during sleep and, in particular, the alterations from before to after sleep when assessed in blood and/or urine. Such changes will be at least partly a consequence of chronic intermittent hypoxia and sleep fragmentation that occurs during sleep.

Keywords: Obstructive sleep apnea, molecular mechanisms, chronic intermittent hypoxia, sleep fragmentation, pathophysiology

Citation: Arnardottir ES; Mackiewicz M; Gislason T; Teff KL; Pack AI. Molecular signatures of obstructive sleep apnea in adults: A review and perspective. *SLEEP* 2009;32(4):447-470.

CURRENTLY THERE ARE A LARGE NUMBER OF POWERFUL TECHNIQUES TO ADDRESS MOLECULAR SIGNATURES OF DISEASE. A MOLECULAR SIGNATURE can be described as a pattern of gene or protein expressions in cells or tissues related to a disease state.[1-4] The vision of evaluating molecular signatures is that they can be used clinically in a number of ways. They may provide diagnostic information, i.e., allow identification of the presence of a disease from a simple blood, urine or even saliva test.[1-4] They may also provide prognostic information, e.g., detecting who with a particular disorder will develop a particular outcome or respond to a particular therapy.[5-11] Approaches include the following: a) assessment of changes in gene expression or protein expression of specific molecules in populations of cells or tissue[12-17]; b) evaluation of the response of relevant cells to in vitro challenges[18-21]; c) discovery strategies, such as gene expression profiling, using mRNA extracted from a population of cells or tissue to study changes in expression of a large number of genes with known and unknown function using microarrays[1,2,5,22-28]; d) proteomics to assess changes in a large number of proteins, including post-translational modifications[2,4,29-37]; and e) global metabolic profiling to discover the differences in a large number of metabolites in cells or tissues due to specific conditions (metabolomics) or as a response to toxic chemicals, drugs, or disease (metabonomics) (Figure 1).[38-42]

Implicit in the approach of molecular signature are 2 concepts. First, a disorder with a physiological level of description that might appear uniform has distinct endophenotypes when molecular signatures are determined. Second, there will be variation between individuals in the response to a particular disorder or challenge. This inter-individual difference is what underlies the concept of personalized medicine.[43,44] These differences in response may, at least in part, reflect genetic variants between individuals.[44-46]

Obstructive sleep apnea (OSA) is, we propose, a condition very amenable to this approach. The physiological measure of OSA is the apnea-hypopnea index (AHI). There is, however, substantial variation both in the nature of the breathing events during sleep and in the consequences of such events in different individuals.[47-49] For example, OSA is often associated with sleepiness,[50-59] hypertension,[60-63] and cardiovascular disease.[64-68] However, a large number of OSA patients are not sleepy,[49,69] and only about half of OSA patients get hypertension,[63] which raises the question: Why do some subjects with OSA develop hypertension and sleepiness while others do not?

The obstructive events during sleep result in changes in molecular processes that can be assessed, thus providing a potential molecular signature for the presence and consequences of OSA. The major current use of this approach is to measure circulating levels of specific biomarkers such as C-reactive protein (CRP) and interleukin-6 (IL-6).[70-75] Newer approaches, such as gene expression profiling and proteomics, are beginning to be

Figure 1—Possible ways to assess molecular signatures in specific cells or tissues.

Figure 2—A schematic illustrating the pathogenetic mechanisms for the consequences of obstructive sleep apnea (OSA) that indicate the areas for potential molecular signatures for the disorder.

applied.[24,31,32,76] In this perspective we describe current data and indicate areas of opportunity. We propose that assessing changes in relevant biomarkers in blood overnight, for example, comparing levels before and after sleep (or an overnight urine test) assessing specific molecules as well as global gene and protein expression, is feasible and likely will be used in the future to assess OSA severity and inter-individual differences in the effects of the disorder. This approach has the potential to transform the practice of medicine in this area by providing diagnostic information as well as showing who will likely benefit from therapy. To fully understand the pathophysiological significance of these molecular signatures, and their relationship with OSA comorbidities, more research in this field related to both OSA and its consequences is needed.

OSA: PATHOGENETIC MECHANISMS AND CONSEQUENCES

OSA is a common condition with a number of adverse consequences.[47,48,77,78] During sleep, individuals with OSA have repeated episodes of declines in breathing (hypopneas) or cessation of breathing (apneas) due to upper airway obstructions. These obstructions result in the following: interruption of sleep with frequent arousals (sleep fragmentation); loss of REM sleep and slow wave sleep (stage 3-4); repetitive decreases in oxygen saturation with rapid reoxygenation causing cyclical deoxygenation/reoxygenation; and repeated changes in intrathoracic pressure and episodic hypercapnia (Figure 2).[47,48,78] A particular advantage in studying this common condition is that there is a safe, effective therapy—nasal continuous positive airway pressure (CPAP)—that can quickly reverse the occurrence of sleep disordered breathing events,[79-81] and the majority of patients show reasonable compliance (device use > 4 hours per night).[82,83]

One of the important questions in a quest to find molecular signatures of a disease such as OSA is which cells or tissue to choose for measurement. Blood, due to its interaction with all organ systems and tissues in the body, its diverse physiological roles as well as being an easily accessible tissue, is an attractive option.[2] Blood is also accepted as a surrogate tissue for conditions where the target tissue is inaccessible (liver, lung).[2,3] Other surrogate tissues that can potentially be used include urine, saliva,[3] and breath condensate.[84] Changes in relevant molecular pathways in blood, urine, and breath condensate have been shown in OSA in various animal and human studies.[15,18,31,32,85-91]

Chronic Intermittent Hypoxia

Much attention on the effects of OSA has focused on the role of chronic intermittent hypoxia (CIH).[92-95] This can be reproduced in animal models, e.g., in rats[96-107] and mice,[108-119] in which a specific pattern of repetitive deoxygenation/reoxygenation can be produced so that causality can be established. CIH can also be produced in cell culture systems to investigate fundamental mechanisms.[120-123]

CIH in mice/rats has been shown to lead to a large number of adverse effects: increased sympathetic activity and hypertension[97,98,107,119,124]; increased catecholamine levels[105,107,113]; liver dysfunction[116]; learning deficits[99-101,103,104,106] with associated damage to cortical and hippocampal neurons[100,101,103,104,112]; persistent hypersomnolence with oxidative damage to wake-active neurons[108,109,111,118]; insulin resistance[110,115]; atherosclerosis when combined with a high-fat diet[116]; and vascular remodeling.[114,119] The activation of the proinflammatory transcription factor nuclear factor κB (NF-κB) pathways has been shown in response to CIH.[15] There is also activation of the transcriptional factor hypoxia induction factor-1 (HIF-1α), a key factor in oxygen homeostasis, which causes direct activation of > 50 downstream

molecules such as erythropoietin (EPO)[95] in response to CIH in animal and cell models.[113,125-128] Activation of HIF-1α plays an important role in the sympathetic response, increased blood pressure and increased triglyceride levels in animal models.[113,127,128] In a recent paper it has been shown that NF-κB is a key transcriptional activator of HIF-1α, linking the proinflammatory and hypoxic response pathways together.[129] Some cell model systems have shown preferential activation of NF-κB over HIF-1α activation[121,122] and one study in rat carotid body showed increased expression of HIF-2α and HIF-3α in response to CIH.[130]

In studies of chronic intermittent hypoxia, the oxygen levels that the animal models and cell cultures are usually exposed to are more severe than the degree of hypoxia typically found in most human subjects with OSA.[97,98,112,124] Thus, the generalizability of the findings needs to be questioned. The level of oxygen saturation in tissue is usually not reported in rodent studies.[100,102,106,112,115] Another difference between patients with OSA and studies in animal and cell models is duration of the insult. Human subjects with OSA may suffer over a long period of time from this condition before they seek medical assistance and are diagnosed.[131] However, in animal or cell models CIH is usually administered for days or weeks.[105,113,122,132] Some investigators have begun to address these issues by measuring the levels of oxygen saturation in tissue and produce less severe hypoxia within each CIH cycle to better simulate the hypoxia levels found in OSA patients in their models.[111,118] A study with longer duration of insult in mice, i.e., 6 months, has also recently been reported.[116]

The effect of intermittent hypoxia has also been assessed in humans. Studies looking at the effects of isocapnic (iso-CO_2) hypoxia for 5 minutes (breathing in 10% O_2) in awake healthy human subjects showed that isocapnic hypoxia causes increased sympathetic activation, increase in blood pressure and hyperventilation through peripheral chemoreceptor stimulation.[133,134] This effect is strongly enhanced by a voluntary apnea at the end of the 5 minute period of hypoxia.[133] Moreover, administration of 100% oxygen to OSA patients during obstructive events diminishes the sympathetic response to apneas.[135] These studies therefore support the findings from animal models that short duration hypoxia leads to increased sympathetic activation.

Cyclical hypoxia with reoxygenation is thought to be like repeated ischemia-reperfusion damage with increased reactive oxygen species (ROS) production during the restoration of oxygen as occurs in an ischemic region when blood flow is restored (ischemia reperfusion).[78,92,136] Thus, OSA is an oxidative stress disorder. CIH and ROS are the central focus of a model developed by Lavie about the pathogenesis of OSA comorbidities.[92,137] According to this model, increased ROS production will lead to activation of NF-κB and hence increased expression of a number of downstream NF-κB target genes, e.g., proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), IL-6 as well as adhesion molecules such as intracellular adhesion molecule-1 (ICAM-1).[92,137] Increases in inflammatory cytokines and adhesion molecules are proposed to lead to activation of various cells such as monocytes, lymphocytes and endothelial cells leading to endothelial dysfunction and cardiovascular disease.[92,137] The evidence supporting this model, both directly and indirectly, comes from studies in both animal models (as described above) and human studies, as will be described below.

Sleep Fragmentation

CIH is not the only physiological challenge that occurs during apneic events; there is also the challenge of sleep fragmentation with repeated arousals. Each of these arousals is associated with a burst of sympathetic activity[138-140] and cardiac changes including surges in blood pressure.[141,142] Repetitive arousals lead to elevated cortisol and lipid levels,[143] increased metabolism,[144] and neurobehavioral deficits as a consequence of sleep fragmentation.[144,145] The role of sleep fragmentation has, however, not received as much attention as chronic intermittent hypoxia. We do know that short sleep duration and chronic partial sleep deprivation over several days are associated with increased risk of hypertension, weight gain, insulin resistance and type 2 diabetes.[146-150] Chronic partial sleep deprivation is also associated with neurobehavioral deficits[151-154] and increased levels of inflammatory markers such as CRP,[155] IL-6,[156] and TNF-α.[156] Even partial sleep deprivation for a single night has been shown to cause increased mRNA expression for IL-6 and TNF-α in circulatory white cells.[157]

Intrathoracic Pressure Changes

The effect of recurrent changes in intrathoracic pressure has been little studied and is often neglected in models of the pathogenetic mechanisms for the consequences of OSA.

The recurring obstructive apneas, which occur with forceful inspiratory effort against an occluded airway, cause significant decreases in intrathoracic pressure.[158] The molecular signature for intrathoracic pressure changes may be atrial natriuretic peptide (ANP), a volume-regulating hormone that functions to decrease the volume within the vascular system as a result of fluid overload.[159] The intrathoracic pressure changes in OSA may cause increased venous dilation of the right atrium causing a "false" signal of fluid overload in the heart and hence increased atrial release of ANP.[159] CIH may, however, also cause pulmonary vasoconstriction, leading to right atrial dilation and increased ANP release.[160]

In support of this hypothesis, ANP has been found to be increased in OSA subjects[161,162] and decreased with CPAP treatment.[161,163-165] ANP increases excretion of both urine and sodium-causing nocturia, which occurs commonly in OSA patients.[159] The increase in ANP has been associated with either the intrathoracic pressure changes[163] or intermittent hypoxia.[163,166] Other studies have, however, questioned the role of OSA in ANP secretion and have found no significant elevation of ANP levels in patients with OSA.[167-169] The short half-life of ANP (2-3 minutes) may be a factor in these negative results.[170,171]

Subjects with what has been called the upper airway resistance syndrome (UARS) show increased upper airway resistance and changes in intrathoracic pressure during sleep, which is usually followed by arousals but occurs without any significant hypoxia.[172] Studies on patients with UARS show that inspiratory efforts causing intrathoracic pressure changes are correlated with both systolic and diastolic blood pressure increases as well as an increased prevalence of hypertension.[173] However, in a pig model, central apneas, which are characterized by no respiratory effort or intrathoracic pressure changes, caused more changes in mean arterial pressure, systemic vas-

cular resistance and cardiac output than obstructive apneas.[174] Another study found similar systemic blood pressure response to obstructive and nonobstructive apneas in an anesthetized primate model.[175]

A sleep apnea model in rats has been recently described where upper airway collapse and reopening is induced by subjecting rats to recurrent positive and negative pressures by means of a nasal mask valve.[176] Overexpression of inflammatory biomarkers, such as TNF-α, was found in the larynx and soft palate tissue in response to these recurrent pressure changes over a period of 5 hours.[176] However, the blood oxygen levels were not reported, and the potential effect of intermittent hypoxia therefore not addressed. Interestingly, snoring-like vibrations applied short-term have also been found to produce similar inflammatory changes in upper airway tissue,[177] supporting the hypothesis that mechanical stimuli may cause inflammatory changes in the upper airway.

These results collectively suggest that intrathoracic pressure changes are not a major contributor to the systemic changes in patients with OSA, but potentially a cause for upper airway inflammation. This pathogenetic mechanism requires further investigation.

CLINICAL EVIDENCE FOR THE MOLECULAR AND PATHOLOGICAL CONSEQUENCES OF OSA

Primary Molecular Domains Affected by OSA

Sleep fragmentation[138-140] and CIH[96-98,135] lead to increased sympathetic activity. Sleep fragmentation and CIH also cause an inflammatory response, and CIH causes oxidative stress. This suggests that the molecular signature for OSA will most likely be found using measures of the following: sympathetic activation, oxidative stress and inflammation. Described below is the evidence for each of these domains and potential biomarkers for each domain.

What Is the Evidence of Increased Sympathetic Activity in OSA?

OSA patients have increased sympathetic activity measured by microneurography (direct recording of muscle sympathetic nerve activity) compared to controls during the daytime,[178,179] that decreases with CPAP treatment.[180-182] Plasma and urine norepinephrine levels which reflect systemic sympathetic neuronal activation,[183] are increased in OSA patients compared to controls,[184,185] but this is not shown in all studies.[179] Many studies have also shown that CPAP treatment reduces noradrenaline levels.[182,186-191] The results for epinephrine levels, which reflect adrenomedullary hormonal activation,[183] are less convincing, as levels were similar in OSA subjects compared to well-matched controls in 2 studies.[184,185] Some studies have found a small decrease with CPAP,[192,193] but not all.[191] Withdrawal of CPAP for one night does not result in a significant increase in norepinephrine levels,[194] but withdrawal for one week significantly increases urinary norepinephrine levels during the daytime but not the nighttime.[195]

Factors influencing the decrease in sympathetic activity with CPAP treatment include CPAP compliance,[180] length of treatment,[181] and whether subjects are initially normotensive or hypertensive.[187] The increase in blood pressure found in many untreated OSA patients is considered, at least partly, a result of their high sympathetic activity.[196,197]

Increased sympathetic activation, such as occurs in OSA, leads to enhanced lipolysis with release of free fatty acids (FFAs), particularly from visceral fat cells.[198-200] Elevated FFAs then activate inflammatory pathways,[201,202] and act as mediators of insulin resistance.[203,204] Interestingly, to date, little research has been done on FFAs in OSA. One recent study found that FFA levels, body mass index (BMI) and AHI were independently associated with insulin resistance in OSA patients but visceral and subcutaneous fat were not.[205] As increased sympathetic activity, inflammation and insulin resistance are all associated with OSA, we propose that elevated FFAs likely have a role in the pathogenesis of OSA consequences. This role remains to be determined.

What is the Evidence That There Is Oxidative Stress in OSA?

The concepts described would posit that there should be evidence of oxidative stress in patients with OSA due to the CIH. A number of studies support this hypothesis.[18,19,86,90,91,206-209] Oxidative stress is, however, difficult to assess.[210-212] Many of the purported measures such as the commonly used thiobarbituric acid reactive substances (TBARS) are nonspecific and were not validated as reliable measures in a multi-institutional study in a rat model designed to assess reliability of methods to assess oxidative stress.[213] Thus, current data need to be interpreted with caution, particularly since many studies have small sample sizes and lack appropriate controls.

Increases in the following purported measures of oxidative stress have been reported in OSA, usually compared to controls and in some studies consequent decreases with CPAP: plasma, exhaled breath condensate and nighttime urinary 8-isoprostane levels as measured with an enzyme immunoassay[90,91,209]; plasma levels of malondialdehyde (MDA)[86]; urinary o,o-dityrosine[86]; plasma levels of TBARS[206,207]; urine levels of 8-hydroxy-2'-deoxyguanosine (8-OhdG), a marker of DNA oxidation[208]; reactive oxygen species (ROS) production in specific subpopulations of monocytes, granulocytes, and neutrophils upon in vitro stimulation.[18,19] However, studies showing no oxidative stress in OSA are also reported.[214-216] Many of the studies performed have either used poorly matched control groups[206-208] or used measures that are controversial regarding their ability to assess oxidative stress.[206,207,216] One study which assessed the reliability of many different oxidative stress measurements in a small group of OSA subjects found that only plasma MDA and urine o,o-dityrosine were appropriate measurements of oxidative stress[86] (This study did not measure 8-isoprostanes.) Given the non-reliability of many of the measures of oxidation, as revealed by recent studies,[86,213] one needs to consider which measure is optimal to assess oxidative changes.

From the many candidates available, the best currently available biomarker for oxidative stress, and the one accepted in the field for in vivo studies,[210-213] is 8-isoprostane (8-iso-PGF$_{2\alpha}$), a marker of lipid peroxidation, measured by gas chromatography/negative ion chemical ionization mass spectrometry (GC/NICI-MS).[210-213] Using immunoassays as has been done in earlier OSA research[90,91,209,214] is more cost-effective but information regard-

ing their precision and accuracy is still largely lacking.[210,212] Hence, data obtained with this methodology may not be reliable. The use of 8-iso-PGF$_{2\alpha}$ has been shown to be a good biomarker for oxidative stress for the following reasons: in vivo formation increases as a function of oxidative stress[212,213]; it is relatively stable in isolated samples of serum and urine[210,212,217]; and it is not influenced by the lipid content of diet.[212] Isoprostanes in blood may occur as free fatty acids or esterified to phospholipids or lipoproteins. Therefore it is important to distinguish between the free and esterified isoprostanes.[212,213] However, both methods seem to give similar results.[213] In plasma the half-life of isoprostanes is very short (1-4 minutes),[218] which makes it important to measure its concentration during the night, not simply in the morning after a night of sleep disordered breathing.[219] In contrast, isoprostane metabolites in urine are more stable and have been found to be an accurate way to measure oxidative stress in humans.[220] They can still be measured 4 hours after exposure.[218] Therefore, the cumulative levels of isoprostanes found in urine after a night of sleep disordered breathing should be measurable in the morning.

Thus, we propose, based on the available data, that the gold standard method for assessing oxidative stress in OSA is measuring 8-isoprostane levels by GC/NICI-MS in urine samples after the sleep period or in plasma during sleep.

What is the Evidence that OSA Increases the Inflammatory State?

Based on the overall oxidative stress model described above,[92,137] increased ROS production should cause increased expression of inflammatory cytokines through activation of NF-κB in OSA patients. However, this is only one postulated model. As stated above, visceral fat and increased sympathetic activity can increase free fatty acid levels which cause an increase in inflammatory cytokines in the absence of ROS.[198-202]

Much of the focus on inflammation in OSA research has been on the markers TNF-α, IL-6, and CRP. Most studies show the following: higher levels of TNF-α and/or IL-6 and/or CRP in plasma of subjects with OSA compared to BMI-matched controls,[71,74,85,90,221-227] and reductions in these inflammatory markers with CPAP therapy when assessed post-sleep.[85,209,223,224] There are, however, also negative studies showing no difference in TNF-α, IL-6, and CRP levels in OSA patients versus matched controls and after CPAP therapy.[73,75,85,228-232] Obesity is the primary factor affecting the levels of the inflammatory markers in many of these negative studies,[73,228,229,231] illustrating the confounding effect of obesity on OSA research and the importance of having well-matched controls. (This issue of confounding by obesity is discussed more fully below.) These differences between studies support our concept of inter-individual differences and heterogeneity of responses in OSA patients that we also describe more fully below.

Other inflammatory effects such as systemic increases in interleukin-8 (IL-8), granulocyte chemotactic protein-2 (GCP-2), monocyte chemotactic protein-1 (MCP-1) levels, and inflammatory cell infiltration in the upper airway have been shown in OSA subjects.[85,233-235] Whether the inflammatory changes in the upper airway occur because of hypoxia, snoring, the mechanical stress of recurrent pressure changes or systemic inflammation or all of the above remains to be answered.[236] Moreover,

whether at least some of the systemic increases in inflammatory biomarkers are due to a "spill-over" effect from the upper airway remains unknown.

Given available evidence on the effects of OSA, the inflammatory markers with the strongest rationale to study further are TNF-α and IL-6. Assessment of each of these has particular challenges. TNF-α may be useful to study dynamic changes. Rapid increase in TNF-α in plasma following apneic events has been described.[88] TNF-α is, however, very sensitive to handling and the blood needs to be processed and frozen immediately for accurate measurements of its levels.[237,238] This procedure should, of course, be applied to all measured biomarkers to avoid artificial changes in their levels. The challenge for IL-6 is that its levels can be artificially elevated over time when blood is obtained from an indwelling intravenous line due to local production by the endothelium.[239-242] This does not apply to TNF-α.[242]

Systemic inflammation is, however, also produced by diseases other than obstructive sleep apnea. Thus, there are a number of confounding effects that need to be considered in assessing these biomarkers (Figure 3). This aspect is discussed more fully below.

Secondary Domains Affected by OSA

The three domains described above represent, in our opinion, the key variables that are affected by the pathogenetic processes in OSA. However, other domains are also affected, such as adipokines,[243-259] adhesion molecules,[260,261] and possibly stress in the endoplasmic reticulum (ER).[111] We now describe evidence for each of these.

What is the Evidence for Changes in Adipokines?

White adipose tissue (WAT) is a metabolically active tissue that produces over 50 molecules termed adipokines with various functions.[262,263] Oxidative stress,[243-248,264-266] inflammation,[243,249-257,264,266-271] and sympathetic activation[259,272] can all affect the expression of adipokines. Therefore OSA potentially affects adipokine levels. A more detailed discussion of the function of the more investigated adipokines now follows.

Leptin:

Leptin is a pleiotropic cytokine with a circadian rhythm in expression, which is produced mainly by WAT and has a regulatory role in body adiposity with high levels acting as a satiety signal.[273-277] Leptin also has an immunomodulatory role[278-281] and is both activated by proinflammatory mediators[249-251] and works as a stimulant of proinflammatory cytokine production such as IL-6 and TNF-α.[282] Leptin levels are increased in obesity,[273] but due to a central leptin resistance that occurs in obesity, it fails its regulatory role in reducing adiposity.[277,283] However, despite the metabolic leptin resistance, high leptin levels still induce sympathetic activation of tissues such as the heart and the adrenal glands,[283] which may contribute to the low-grade systemic inflammation and development of hypertension in obesity.[283-285] Leptin acts as an independent risk factor for cardiovascular disease.[286-288] Hyperleptinemia and hyperin-

Molecular Effects of OSA

Oxidative Stress

↑Sympathetic activity
↑noradrenaline

Adipokines
↑leptin
↑resistin
↓adiponectin

Upper airway inflammation

Adhesion molecules
↑ICAM-1
↑VCAM-1
↑selectin

↑FFA production

Unfolded protein response

Systemic Inflammation

NF-κB activation
↑CRP   ↑IL-6   ↑TNF-α

Confounding Effects

Obesity and visceral fat

Smoking

COPD

Asthma

Type 2 diabetes

Cardiovascular disease

Other inflammatory disorders

Figure 3—Possible pathways for systemic inflammation in OSA subjects. Displayed are both the different molecular pathways that can occur in OSA and confounding effects of other diseases and lifestyle choices.

sulinemia are both commonly found in obesity[289]; insulin acts as a stimulant of leptin production,[290,291] and the resistance to both leptin and insulin due to overfeeding occurs quickly and simultaneously.[292] Paradoxically to other leptin functions, leptin is considered anti-diabetic and can hinder the effects of insulin on lipid oxidation and production.[293-295]

OSA patients have been found to have higher leptin[70,185,232,296,297] measured in the morning than BMI-matched controls in all but one study looking at obese subjects only.[298] There is, however, a potential difference in visceral fat volume despite the BMI matching (discussed more fully below).[232] CPAP therapy reduces leptin levels in OSA patients,[70,298-302] but the reduction is more pronounced in non-obese than obese patients,[70,298,301] and one study found no change in obese OSA subjects.[298] In obese OSA patients with type 2 diabetes only a trend for a decrease in leptin level was found after 3 months on CPAP and the change was not significant.[303]

Adiponectin:

Adiponectin, produced by mature adipocytes,[304,305] increases oxidation of fatty acids[306] and has inhibitory effects on glucose synthesis by the liver.[307] Unlike leptin, adiponectin shows no circadian rhythm but has some apparently random fluctuations

in levels across the day and night.[273] Despite being produced by adipocytes, adiponectin levels decrease with increased fat stores,[258] and a decrease in adiponectin levels is associated with obesity, cardiovascular disease, insulin resistance and type 2 diabetes.[258,273,308-312] It has an anti-inflammatory function, as it inhibits NF-κB activation and hence production of IL-6 and TNF-α.[313-315] It also induces production of the anti-inflammatory interleukin-10 (IL-10).[316] Oxidative stress, TNF-α, and IL-6 all inhibit adiponectin production,[247,248,252,253,258] hence potentiating their effects.

Adiponectin levels have been shown to be lower both in the morning and evening in OSA patients compared to BMI-matched controls.[308,317,318] However, other small studies have found increased adiponectin levels in the evening in OSA patients[319] and no difference in the morning from controls.[185] One study found a nocturnal decrease in adiponectin levels in severe OSA, which was not found in controls or milder OSA.[318] Results from studies looking at the effect of CPAP therapy on adiponectin levels are also conflicting. Two studies found no immediate changes in adiponectin levels in the morning with CPAP,[308,320] while one study found a decrease after 2 days on CPAP (time of day of measurement is unclear),[321] and another found a reduction in a nocturnal decrease of adiponectin after one night of CPAP.[318] Two small studies have also given conflicting results about long-term effects of therapy. One found an increase in adiponectin levels after long-term CPAP therapy[320] but the other no change from baseline levels.[321] Finally, a larger study that measured visceral and subcutaneous abdominal fat (by computerized tomography) in untreated OSA patients found no relationship between morning adiponectin levels and OSA severity, but did find a relationship with visceral fat area and body weight.[205]

Therefore the question whether adiponectin has a role in the pathogenetic consequences of OSA or whether its levels are affected by OSA remains unclear. Further studies assessing both abdominal fat volume and adiponectin levels across the day and night in OSA patients, when untreated and on CPAP, are needed to address this issue as OSA possibly affects the usually random secretion of adiponectin[273] and causes it to decrease across the night.[318]

Resistin:

Resistin is almost exclusively expressed in WAT in murine models[322] but is expressed in high levels in other tissues such as bone marrow and macrophages in humans and associated with the immune system.[323-327] Resistin has been implicated in insulin resistance based on research in rodent models,[322,328-330] but the data from human studies are controversial.[310,331,332] Resistin appears to have a role in inflammation[333,334] and has been shown to be both activated by, and cause activation of, IL-6 and TNF-α through the NF-κB pathway in peripheral blood mononuclear cells.[254,255] In adipocytes, however, IL-6, TNF-α and epinephrine either have no effect on or downregulate resistin production.[256,259,335] Antioxidant treatment causes decreased resistin levels in serum,[246] indicating that oxidative stress has some regulatory role in resistin production. Resistin has been shown to induce the production of adhesion molecules and be increased in patients with coronary artery disease,[336,337] suggesting that it has a role in atherogenesis.

Two small studies to date have looked at the relationship between resistin and OSA in adults. One study looking at obese subjects with severe OSA found that resistin levels were related to obesity, inflammation and atherogenesis, not to OSA, and did not change with CPAP.[338] The other study looked at less obese OSA subjects with different disease severity and controls. They found that resistin levels and inflammation levels were related but also found increased resistin levels with increased OSA severity and a reduction with CPAP.[339] A study in children with OSA found no relationship between resistin levels and OSA.[340] However, since inflammatory cytokines affect resistin levels and vice versa, and resistin has a potential role in atherogenesis, further studies are needed to address whether OSA alters resistin levels. This relationship between resistin and OSA is potentially dependent on OSA severity and obesity levels.

Other Newly Discovered Adipokines:

Other adipokines, recently discovered, include visfatin, apelin, vaspin, and hepcidin.[262] These adipokines have not yet been studied in the context of OSA but hepcidin has been suggested as a marker of OSA.[341]

Studies looking at the relationship between OSA, obesity and these adipokines are of interest as they are regulated by many of the same molecular processes as are found in OSA pathophysiology (e.g., hypoxia and inflammation).[243-245,252,264-272] This is a future direction for research.

What is the Evidence of Increased Adhesion Molecules in OSA?

The release of cellular adhesion molecules, which promote adhesion of circulating leukocytes to endothelial cells, is potentially one of the first steps in the pathogenesis of atherosclerosis.[342] The release of cellular adhesion molecules can be stimulated by inflammatory cytokines, oxidative stress as well as other mechanisms such as lipopolysaccharide.[260,261,343-346]

A variety of cellular adhesion markers, such as ICAM-1, vascular adhesion molecule-1 (VCAM-1), E-selectin, and L-selectin, have been shown to be elevated in OSA compared to controls.[72,227,347-350] However, not all studies used well-matched controls,[227,347,348] and none matched for visceral fat. More convincing is the demonstration that adhesion molecules are reduced with CPAP treatment.[347,349,351]

What is the Evidence of Changes in the Unfolded Protein Response in OSA

Stress in the endoplasmic reticulum (ER), caused by a disruption of protein folding and buildup of unfolded proteins in the ER,[352] occurs in response to stressors such as hypoxia[353,354] and cholesterol loading[355] and in conditions such as obesity[356,357] and type 2 diabetes.[352,358] ER stress causes the unfolded protein response (UPR), an adaptive response which increases the upregulation of ER chaperones and downregulates protein translation in order to reestablish normal function of the ER.[352] The UPR has been shown to occur in the liver of obese mouse models[356] and fat of obese subjects (not in lean).[359] UPR has a role in initiating insulin resistance in obesity,[356] as well as in promoting atherosclerosis[355] and possibly inflammation.[359]

Increased expression of the prototypical molecular chaperone termed binding immunoglobulin protein (BiP, also known as GRP78), phosphorylation of PKR-like ER kinase (PERK) and the eukaryotic initiation factor 2-α (eIF2α) can be used as molecular signals that indicate activation of the UPR.[352,358,360]

A recent study provides support for the presence of ER stress in OSA as CIH in mice leads to increased phosphorylation of PERK and other changes signalling upregulation of the UPR in motoneurons.[361] Total sleep deprivation has also been found to activate the UPR in the brain of different animal models.[25,362-367] Research on the UPR in OSA is of interest, and it is conceivable that it will be activated across the sleep period in circulating cells.

POTENTIAL CONFOUNDING EFFECTS ON THE MOLECULAR SIGNATURES OF OSA

Confounding Effects of Obesity

Obesity, in particular central obesity, is the most important risk factor for OSA.[69,368-374] OSA with complaints of excessive sleepiness affects 4% of middle-aged males and 2% of middle-aged females,[69] but among obese subjects, these percentages are much higher.[69,371,372,375-378] OSA prevalence in morbidly obese subjects requiring bariatric surgery has been found to be between 40% and 94%.[372,375-378]

Both obesity and OSA have been shown to be independent risk factors for insulin resistance, hypertension, and cardiovascular disease (for reviews on OSA, see[47,48,78]; for reviews on obesity, see[379-381]). Insulin resistance is also an independent risk factor for hypertension and cardiovascular disease.[382]

Intervention studies based on treating subjects with OSA with CPAP have shown improvements in insulin resistance[303,383,384] and hypertension.[385-390] An observational study found improvement in glucose control in obese type 2 diabetics with OSA treated with CPAP,[391] but a randomized trial of CPAP therapy in very obese type 2 diabetic OSA patients found no improvements in glucose control with CPAP.[392] Meta-analysis of treatment trials suggests that the effects of treatment of OSA on blood pressure are modest.[386]

Because OSA and obesity commonly coexist and have been shown to have similar clinical consequences, it is important to consider their relative roles in causing adverse clinical consequences; it is also important to delineate the relative importance of shared common pathways and whether there are unique pathways related to OSA that mediate clinical consequences. The key pathogenetic mechanisms resulting from OSA, i.e., oxidative stress, inflammation and sympathetic activation, also occur in obesity,[393-398] and have a role in insulin resistance.[399-406] Thus, at this mechanistic level both obesity and OSA affect the same processes, and their relative roles in oxidative burden, the inflammatory state (see Figure 3), and sympathetic activation need to be assessed. Unfortunately, the large literature on obesity simply ignores this issue. In a recent meta-analysis of studies demonstrating a link between obesity and cardiovascular disease published in *Lancet*,[407] sleep disordered breathing was not assessed in a single study, which, from a scientific perspective, is an important omission. This is an important question to address, since there is a safe, effective therapy available for OSA

(i.e., CPAP).[79,81] CPAP treatment of OSA in obese individuals has the potential to alter the cardiovascular consequences of obesity.

A critical issue is how to determine the relative role of OSA. One commonly used strategy is to assess differences between OSA patients and controls without OSA but matched for BMI. Matching for BMI is likely, however, not to be sufficient. Abdominal visceral fat has been shown to be a stronger risk factor than other fat tissue for adverse health consequences and is associated more strongly with hypertension, insulin resistance, diabetes, the metabolic syndrome than other fat deposits.[408-412] Further evidence that visceral fat rather than other fat deposits is causal (not only associative) for insulin resistance is, however, needed.[413] Visceral fat is also a risk factor for OSA and has been shown to be increased in OSA patients compared to BMI-matched controls.[232,368,414] Visceral fat, therefore, plays an important part in understanding of OSA pathophysiology moving forward and needs to be directly assessed in studies of OSA.

An alternative and more powerful strategy to separate the effects of obesity and OSA is to use a within-subject design, i.e., assess differences before and after effective CPAP therapy. This strategy has been used in multiple studies.[19,85,91,189,206,209,223,224,320,385,389,391,392,415] There are, however, problems with this strategy. First, there are data to indicate that successful CPAP therapy reduces the amount of visceral fat,[299,302] albeit by a small amount (8% to 16% over a period of 3-6 months). Thus, changes with CPAP treatment could be due, at least in part, to reductions in visceral fat mass. Moreover, in patients with OSA who are effectively treated with CPAP, there could be irreversible effects of OSA. OSA is a chronic, slowly progressive disorder,[371] and it can be present for years before it is diagnosed.[131,376,416] Residual sleepiness in OSA has been described,[417] i.e., persistent sleepiness even on effective CPAP therapy. This effect might be mediated, at least in part, by oxidative damage to wake-active neurons.[108,109,111,118] There could also be vascular wall remodeling that occurs during the years with untreated OSA.[119] Currently the magnitude of irreversible effects of untreated OSA is largely unknown. Studies are needed to estimate the reversible effects of OSA (differences pre- to post-CPAP in effectively treated individuals) and irreversible effects of OSA, i.e., estimate the difference between patients with OSA after effective treatment when compared to controls with similar levels of visceral fat but not with OSA.

Since both free fatty acids and proinflammatory cytokines are produced by visceral fat,[200,397,418] it is likely that for equivalent degrees of OSA, there will be an enhanced production of these biomarkers in obese subjects as a consequence of OSA in comparison to lean subjects with OSA. Since obesity in the absence of OSA can lead to production of these biomarkers, we would anticipate that obese individuals with OSA will have higher levels of biomarkers even after effective treatment of OSA than lean subjects. Comparison of biomarkers in individuals with different degrees of visceral fat, all of whom are effectively treated for OSA, will provide the much needed estimate of the effect of obesity per se. In such studies, waist circumference can be used, since waist circumference is increasingly recognized to be the best proxy for the degree of

visceral adiposity.[419,420] But direct measurement of both visceral and subcutaneous fat distribution would add more definitive information, as waist circumference cannot distinguish between subcutaneous and visceral fat. A study by Vgontzas et al[232] emphasizes the importance of matching for visceral fat between groups in studies of OSA. In this study, plasma levels of IL-6, TNF-α, and leptin in the evening and morning were measured. Obese OSA patients were found to have the highest levels of the 3 biomarkers, obese controls without OSA intermediate levels, and lean controls the lowest.[232] However, the OSA patients also had more visceral fat than the obese controls, confounding the results.[232] Thus, directly assessing visceral fat is required to answer these questions.

Other Coexisting Conditions

Systemic inflammation, a key aspect of pathological mechanisms for the consequences of OSA, also occurs in cardiovascular disease,[421-425] type 2 diabetes,[426,427] asthma[428,429] and smoking,[430-432] all of which are commonly found in patients with OSA (see Figure 3).

Oxidative stress is another key element in OSA but is also increased with type 2 diabetes,[433-435] smoking,[432,436] cardiovascular disease,[424,437] age,[438] and joint diseases.[439]

Sympathetic activation has also been shown to be increased in cardiovascular disease,[421,422] the metabolic syndrome,[394,421,440] and insulin resistance[440]—all conditions commonly found in OSA patients.[67,441-443]

Thus, establishing the actual role of OSA is challenging, and will require study designs that deal with the confounding effect of obesity and the coexistence of other conditions that affect the same mechanisms as OSA does.

INTER-INDIVIDUAL DIFFERENCES IN OSA

Variability in the Nature of OSA

Differences between individuals with OSA may be directly related to the nature of their sleep disordered breathing events. Some individuals with OSA have marked sleep fragmentation with little, if any, intermittent hypoxia, while others may show marked intermittent hypoxia with lesser degrees of fragmentation. Within an individual the magnitude of hypoxia and arousals may vary across the sleep period. We propose the need for studies that capture this source of variability by recruiting subjects from both extremes of the spectrum (with regard to severity of intermittent hypoxia and number of arousals) and assess associations between changes in biomarkers and the nature of the sleep disordered breathing events both between and within individuals.

Heterogeneity in the Biological Response

The change in molecular pathways between different individuals for identical degrees of sleep disordered breathing is also unlikely to be the same. There will likely be inter-individual differences in response. Such inter-individual differences might be seen as a challenge but represent, in our view, another opportunity. We know that many individuals with OSA

do not have excessive sleepiness,[69] and only about 50% of OSA subjects develop hypertension.[63] The question is why—why do some subjects with OSA develop hypertension and cardiovascular disease while others do not? One possibility is that individuals who develop hypertension and cardiovascular disease have increased pathogenetic responses or decreased adaptive response for equivalent degrees of OSA.

Such heterogeneity in response might be related to differences in protective mechanisms. Individuals vary in their antioxidant ability, which is complex, as it involves dietary factors and multiple intrinsic antioxidant systems.[444,445] Candidates for measurement are numerous, including antioxidant enzymes (such as superoxide dismutates and glutathione peroxidases), non-enzymatic antioxidants (such as glutathione, bilirubin, and vitamins C and E), and melatonin, which has a role in the regulation of antioxidant enzyme activity and expression.[445,446] Measurements of total antioxidant capacity that are meant to functionally assess the total antioxidants in plasma or serum are also used but the reliability of these assays and what they actually measure is questionable.[447]

The question whether there is a change in antioxidant levels in OSA patients remains unanswered. The studies done so far have been relatively small, used various methods for assessing them and have contradictory results.[24,86,207,216,415,448,449]

Levels of anti-inflammatory molecules such as IL-10 can also vary between individuals.[6,450] IL-10 has a primary role in restricting inflammatory responses[451] and has a role in protecting against atherosclerosis,[452,453] insulin resistance,[6,454] and type 2 diabetes.[450] Thus, individuals with OSA and comorbidities may have lower IL-10 levels than those without comorbidities.

IL-10 levels have been reported to be lower in non-obese children with OSA than controls and increased after tonsillectomy and adenoidectomy in children with OSA.[455] IL-10 expression in T cells has been negatively correlated with the severity of OSA.[456] One study showed that IL-10 levels were decreased in the evening in OSA patients compared to ill-matched controls[88] but another study with better controls found no difference.[85]

Adaptive responses that affect sympathetic activation are also potentially heterogenous between individuals with OSA. Likely candidates include differential downregulation of adrenergic receptors[457] and differences in norepinephrine clearance rates,[458] both of which act to diminish the stimulatory response and the increased sympathetic activity in OSA.

Differences between those with OSA with comorbidities and those without could be genetic in origin. There is now a large literature on genes conferring risk for hypertension, insulin resistance and CV disease.[459-463] Polymorphisms in genes affecting oxidative stress, inflammation and sympathetic activity[464-466] are also of high interest. There is a limited but growing number of candidate gene studies addressing the question of gene variants and their pathophysiological effect in the OSA population.[467-475] More studies in this field are clearly needed, preferentially using more high-throughput technology such as genome-wide association, custom genotyping arrays such as the new cardiovascular chip to look for single nucleotide polymorphisms associated with increased risk for comorbidities in individuals with OSA, copy number variations as well as gene-gene and gene-environment interactions.[476-478]

THE CONCEPT OF A TEMPORAL MOLECULAR SIGNATURE FOR OSA

One approach to understanding the clinical variability in the consequences of OSA in different subjects is to evaluate the molecular signatures of the disorder.[2,43,44] There are certain aspects that we believe make OSA unique: a) the pathogenetic events occur in a temporally controlled fashion, i.e., during sleep; and b) the nature of the pathogenetic events can be characterized, e.g., breathing cessations, sleep fragmentation, hypoxia, cyclical deoxygenation/reoxygenation, etc. These concepts would argue that if we are to develop a molecular signature of OSA we should focus on the *temporal* changes taking place across the sleep period and relate these to the postulated pathogenetic events. Such temporal changes during sleep might, of course, in part, be related to circadian factors and/or alterations in sleep stages. There is, for example, circadian control of molecules (such as melatonin) and functions (such as body temperature)[274,479-481] and a sleep-stage specific regulation of others, such as plasma catecholamine concentration,[482] heart rate variability,[483] thermoregulation, and sweating.[484] To initially evaluate this source of temporal variability it will be necessary to study OSA subjects before and while on an effective therapy with CPAP as well as matched controls with no OSA. The changes in sleep stages usually seen with successful CPAP treatment[485,486] are harder to control for but can at least be addressed as covariates in statistical models of larger studies, as there are substantial inter-individual differences in the sleep stage architecture in untreated OSA patients and changes with treatment.[82,487]

Thus, we believe that the optimal molecular signature for OSA is likely to be change in relevant biomarkers across the sleep period; that is to measure the change from pre-sleep to post-sleep. An advantage of assessing an overnight change, instead of a single time point, is that many of the molecular mechanisms activated by OSA are shared by other common conditions (as discussed earlier), particularly obesity,[393-398] cardiovascular disease,[423-425,437] and type 2 diabetes.[426,427,433-435] Assessment of biomarkers at a single time point will be confounded by these conditions, whereas overnight changes due to the challenge of OSA will give, in our view, a clearer picture of the contribution of OSA.

Given the postulated relationship between breathing events during sleep and the molecular process we are assessing, there is a strong rationale for the overnight change to be an ideal molecular signature for OSA. Previous data to support this assertion are, however, limited since most studies have simply measured biomarkers in a single sample in the morning, i.e., post-sleep. Available data from studies looking at overnight change in OSA, which are scant, support this hypothesis that studying change across the sleep period will give more information than a single sample: a) progressive increase in the oxidative stress marker MDA across the night in patients with OSA that correlates with the percentage of time with $SaO_2 < 85\%$[86]; b) an almost 3-fold increase in plasma TNF-α levels after the first hypoxic apneic event of the night with oxygen saturation below 85% in OSA patients compared to pre-sleep levels[88]; c) 24-hour measurements of erythropoietin that showed attenuation in oscillation and changed peak values from untreated to

Table 1—A Comparison of Biomarker Assessment at a Single Time-point Versus Overnight Measurement

	Single Time-Point	Overnight Measurement (repeated)
Time of Measurement	Generally in the morning following OSA events	During OSA events and at different sleep stages
Circadian rhythm detection	No	Shows changes in amplitude and shifts in circadian rhythm
Assessment of dynamic changes during sleep	No	Detects rapid changes in biomarkers (e.g., TNF-α, 8-isoprostanes)
Assessment of confounders	Limited	Shows acute effects of OSA vs. combined chronic effects of OSA and comorbidities
Reliability of measurement	Single sample more affected by measurement errors and biological variations	Multiple samples less affected by measurement errors and biological variations

CPAP treated subjects;[488] and d) acute changes in sympathetic activity and blood pressure during apneas.[196]

Our postulate that overnight measurements of change in biomarkers will provide superior diagnostic ability for OSA than post-sleep measurements only is that it addresses the problems of coexisting conditions such as obesity. It takes advantage of the temporal nature of OSA. This postulate needs to be tested further, as there are limited studies addressing this issue to date and more research is clearly needed. We summarize in Table 1 what we propose are the advantages of overnight measures (repeated samples) compared to assessments at a single time-point.

COMBINING A TEMPORAL STRATEGY WITH NEWER APPROACHES

Gene Expression Profiling

Microarrays are increasingly being used to evaluate potential molecular signatures of disease.[23,489,490] They offer the advantage of providing a broad unbiased approach to study changes in gene expression of thousands of genes simultaneously and the ability to discover new pathways and molecules affected by a disease such as OSA.[1,2] The main disadvantage is the cost of this high-throughput technology.

Whether looking at the gene expression of specific genes or using a microarray approach, investigators need to be aware of the sensitivity of mRNA to storage and handling. mRNA expression continues to change after blood or other tissue is extracted, if the tissue is not immediately suspended in chemicals to kill the cells and the tissue is kept frozen.[491-498] For example, after 4 hours of storage at room temperature of whole blood with EDTA, there is a 10- to 100-fold increase in expression of IL-8, c-myc, and c-fos.[491] Care must also be taken with the statistical analysis of microarray data, as well as with other high-throughput methods, such as proteomics, metabolomics, and lipidomics, because of the multiple comparison issue. Complex statistical analyses have been designed for this purpose.[499-506]

To date, there have been 2 studies looking at gene expression profiling in OSA patients: one in adult patients[24] and one in non-obese children with OSA.[76] In the study in adults, gene expression was measured both before and after sleep, albeit in a small sample (4 OSA patients, 4 controls), therefore allowing for the assessment of overnight changes in gene expression. In OSA patients, but not controls, overnight upregulation of expression of oxidative stress responsive genes such as the antioxidant enzymes superoxidase dismutase 2 (SOD2) and catalase were found as well as downregulation of other genes, such as superoxidase dismutase 1 (SOD1).[24] Overnight changes in OSA patients, but not controls, were also found in genes that modulate the cell cycle.[24] In the study on pediatric OSA,[76] gene expression changes in leukocytes were assessed at a single time point (post-sleep) in 20 non-obese children with OSA and 20 well-matched controls. Differences between these groups were found in a number of genes involved in various biological pathways, including genes such as interleukin-27 in the inflammatory pathway. These studies show the promise of this approach, but need to be done in a larger number of subjects to assess inter-individual differences in response (see above). As argued earlier, temporal changes in gene expression across the sleep period will, we propose, provide the most information.

Proteomics

Proteomics is a discovery strategy, similar to gene expression profiling, that examines expression of proteins and post-translational modifications of thousands of proteins simultaneously.[4,36,37,507,508] The benefits of proteomics is to obtain information regarding changes in protein quantities, post-translational modifications, and protein-protein interactions.[509] This information is needed to understand the true molecular phenotype of a disease since knowledge on gene variants, and changes in gene expression levels, may not translate into actual changes in protein.[510]

Proteomics is more complicated than genomics and the state of the technology is not as developed as microarrays. Major issues with proteomics are the sheer number of proteins compared to genes (100-fold increase) and mRNA (10-fold increase), the huge difference in protein concentrations of the dynamic range of 10^{10} as well as the myriad post-translational modifications that alter the protein signatures of samples (see [510]). The most employed proteomics technologies today include 2-dimensional gel electrophoresis and/or HPLC coupled to different mass spectrometry approaches. A discussion on the advantages and disadvantages of the different technologies is beyond the scope of this paper but for an excellent review see Gulcicek.[510]

An important issue with proteomics is that of protein abundance; abundant proteins tend to be overrepresented in studies, while less abundant proteins are often not detected. This is especially important/true in plasma proteomics, in which 99% of plasma is comprised of 22 highly abundant proteins, and most of the clinically interesting biomarkers are found at much lower levels.[509,511] Immunoaffinity depletion of samples as well as the use of fluorescent dyes with greater dynamic ranges are being used to address this problem. Proteomics in blood can be done either on plasma or serum. The use of plasma is considered superior to serum for at least certain proteome measurements, as approximately 40% of signals found in serum are not found in plasma because of ex vivo generation during clotting.[512] Urine proteomics is also considered a promising method for new biomarker discoveries in relation to various systemic diseases.[4] Urine analysis has the potential to find changes in circulating proteins and peptides that are small enough to pass through the glomerular filter; it is therefore not isolated to diseases related to the kidneys but all diseases that have an effect on circulating molecules.[4]

Only two studies have been published looking at proteomic patterns in relation to OSA. Both studies come from the same research group investigating OSA in children.[31,32] One study assessed the serum proteomics patterns associated with OSA in children and found that 3 proteins differed in expression between children with OSA and those with snoring only. Assessment of the proteins could predict OSA diagnosis with a sensitivity of 93% and specificity of 90%.[32] One of the 3 proteins was identified as osteocalcin, a precursor for a γ-carboxyglutamic acid-containing protein that has been used as a biomarker for growth retardation,[32] an important consequence of OSA in children.[513] The other study assessed the difference in first-morning urine samples between children with OSA and controls and found significant differences in the expression of 2 proteins: gelsolin (severs actin filaments when activated) and perlecan (a heparin sulfate proteoglycan), between the 2 groups.[31] These interesting findings need to be replicated by other studies.

Metabolic Profiling

Metabolic profiling, the global analysis of metabolites found in a tissue or cell under specific conditions (also known as metabolomics) and the response of a tissue or cell to a disease or drug toxicity (also known as metabonomics),[41,42,514-516] is still in its infancy and currently has its share of technical problems.[42,517,518] Metabolic profiling, however, has the potential to shed further light on the molecular signature of diseases such as OSA in conjunction with other high-throughput techniques.

No studies using this approach have been done in the field of OSA but studies looking at diabetes[39,40,519] and cardiovascular disease[38,519,520] show initial promising results. This will likely be a topic of more studies in the future.

Investigating a Cellular Window

Measuring circulating biomarkers in plasma or assessment of molecules in urine can be used to estimate the changes in biomarkers due to OSA. Another approach is to assess changes in specific cell populations in blood. This provides a more cellular approach to the quest of finding biomarkers for OSA, and

gives researchers the opportunity to look at intracellular mechanisms without employing invasive measures to look at affected organs. Such cellular approaches have already been applied successfully to study the effects of obesity and cardiovascular disease, hypoxia and seizures.[13,14,16,20,23,27,521] While earlier studies using this approach often used all white blood cells to study changes,[14,16,23,521] there is, not surprisingly, a heterogeneity in response of different cell types.[27] Therefore studies have started focusing on changes in specific subpopulations of leukocytes, such as monocytes.[20,224,489,522] Recruitment of circulating monocytes into adipose tissue[523] and inflamed intima[524,525] has been implicated in insulin resistance/type 2 diabetes and atherosclerosis, respectively, both of which are considered comorbidities of OSA.[48,78] Monocytes have also been shown to be affected specifically by OSA, e.g., by NF-κB activation,[21] increased production of TNF-α,[21,224] and IL-6.[223] Other subpopulations of leukocytes such as lymphocytes have also been examined in patients with OSA.[456,526-528] Different subpopulations of T lymphocytes are activated and more cytotoxic in OSA patients.[456,526,527] Lymphocytes also have less repair capacity for DNA damage in OSA patients.[528] Therefore, studying molecular changes in different subpopulations of circulating cells provides additional opportunities for establishing molecular signatures for OSA.

CONCLUSION

Throughout this review and perspective, we have provided information to support our assertion that there are major opportunities to establish molecular signatures for OSA. These opportunities include both hypothesis-driven studies on specific pathways and use of broad discovery strategies such as expression profiling, proteomics, and metabolomics. Investigating changes in gene or protein expression in specific circulating cells will likely provide the clearest signatures.

Part of the challenge for establishing a molecular signature for OSA is that obesity, which is commonly associated with OSA, leads to activation of the same pathways as does OSA. This suggests that we need approaches to separate the effects of OSA from that of obesity per se. Examining the overnight change in relevant biomarkers across the sleep period is, we propose, the optimal strategy to do so.

It is conceivable that since changes in molecules in key pathways across the sleep period will be the consequence of the aberrant breathing events, considerable information about these events can be obtained from simple blood and/or urine tests, without the need for overnight recording of many physiological variables. It is likely that the changes across the sleep period will reflect the degree of free radical production, as a consequence of cyclical intermittent hypoxia, and the degree of hypoxia potentially assessed by looking at HIF-1α expression in circulating cells as well as levels of proteins whose level is affected by HIF-1α.

It is conceivable that establishing molecular signatures for OSA will provide not only diagnostic information, but also prognostic information, i.e., which person with OSA is likely to develop specific consequences. We need to focus on inter-individual differences within the OSA population and the heterogeneity in response to the disease between individuals. It is important to evaluate the sources of this inter-individual variability. Developing and validating molecular signatures for OSA will

be a major part of this effort. It will complement genetic studies to make the goal of personalized sleep medicine a reality.

The biomarkers studied in the OSA field to date, are neither sensitive nor specific enough to be a molecular signature for OSA since changes in levels of the biomarkers studied are also found in many of the comorbidities of OSA. One of the major thrusts of this review is to urge investigators to collect data in a manner that allows us to evaluate what happens temporally to biomarkers across the sleep period, by sampling at times that are more specific to elucidating differences due to OSA. These studies are not at present at the stage of clinical application but the experimental approaches outlined here are likely to lead in the future to new approaches to diagnose as well as providing prognostic information. The future clinical utility in routine practice will of course be determined by the results of such studies.

Thus, much investigation remains to be done. We now have the tools to study candidate pathways and also take broader unbiased approaches. When combined with assessment of temporal change across the sleep period, we can fully address whether, as we propose, measuring molecular signatures of OSA will provide critical new and relevant information for diagnosis and management of patients with obstructive sleep apnea.

ACKNOWLEDGMENTS

DISCLOSURE STATEMENT

REFERENCES

1. Kittleson MM, Hare JM. Molecular signature analysis: using the myocardial transcriptome as a biomarker in cardiovascular disease. Trends Cardiovasc Med 2005;15:130-8.
2. Mohr S, Liew CC. The peripheral-blood transcriptome: new insights into disease and risk assessment. Trends Mol Med 2007;13:422-32.
3. Rockett JC, Burczynski ME, Fornace AJ, Herrmann PC, Krawetz SA, Dix DJ. Surrogate tissue analysis: monitoring toxicant exposure and health status of inaccessible tissues through the analysis of accessible tissues and cells. Toxicol Appl Pharmacol 2004;194:189-99.
4. Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ 2007;177:361-8.
5. Hakonarson H, Bjornsdottir US, Halapi E, et al. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc Natl Acad Sci U S A 2005;102:14789-94.
6. Scarpelli D, Cardellini M, Andreozzi F, et al. Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in caucasian italian subjects. Diabetes 2006;55:1529-33.
7. Lemaitre RN, Heckbert SR, Sotoodehnia N, et al. beta1- and beta2-Adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke. Am J Hypertens 2008;21:290-6.
8. Shearman AM, Cooper JA, Kotwinski PJ, et al. Estrogen receptor alpha gene variation is associated with risk of myocardial infarction in more than seven thousand men from five cohorts. Circ Res 2006;98:590-2.
9. Bohen SP, Troyanskaya OG, Alter O, et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci U S A 2003;100:1926-30.
10. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
11. Kittleson MM, Minhas KM, Irizarry RA, et al. Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. Physiol Genomics 2005;21:299-307.
12. Tsiotra PC, Tsigos C, Yfanti E, et al. Visfatin, TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. Horm Metab Res 2007;39:758-63.
13. Lupattelli G, Marchesi S, Ronti T, et al. Endothelial dysfunction in vivo is related to monocyte resistin mRNA expression. J Clin Pharm Ther 2007;32:373-9.
14. de Mello VD, Kolehmainen M, Schwab U, et al. Effect of weight loss on cytokine messenger RNA expression in peripheral blood mononuclear cells of obese subjects with the metabolic syndrome. Metabolism 2008;57:192-9.
15. Greenberg H, Ye X, Wilson D, Htoo AK, Hendersen T, Liu SF. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 2006;343:591-6.
16. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004;110:1564-71.
17. Yndestad A, Holm AM, Muller F, et al. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003;60:141-6.
18. Schulz R, Mahmoudi S, Hattar K, et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000;162:566-70.
19. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002;165:934-9.
20. Foldes G, von Haehling S, Okonko DO, Jankowska EA, Poole-Wilson PA, Anker SD. Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. Int J Cardiol 2008;124:80-5.
21. Yamauchi M, Tamaki S, Tomoda K, et al. Evidence for activation of nuclear factor kappaB in obstructive sleep apnea. Sleep Breath 2006;10:189-93.
22. Tang Y, Lu A, Aronow BJ, Wagner KR, Sharp FR. Genomic responses of the brain to ischemic stroke, intracerebral haemorrhage, kainate seizures, hypoglycemia, and hypoxia. Eur J Neurosci 2002;15:1937-52.
23. Tang Y, Lu A, Aronow BJ, Sharp FR. Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fingerprints of disease. Ann Neurol 2001;50:699-707.
24. Hoffmann MS, Singh P, Wolk R, Romero-Corral A, Raghavakaimal S, Somers VK. Microarray studies of genomic oxidative stress and cell cycle responses in obstructive sleep apnea. Antioxid Redox Signal 2007;9:661-9.

25. Mackiewicz M, Shockley KR, Romer MA, et al. Macromolecule biosynthesis: a key function of sleep. Physiol Genomics 2007;31:441-57.

26. Zimmerman JE, Rizzo W, Shockley KR, et al. Multiple mechanisms limit the duration of wakefulness in Drosophila brain. Physiol Genomics 2006;27:337-50.

27. Du X, Tang Y, Xu H, et al. Genomic profiles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: comparisons to ischemic stroke, migraine, and Tourette syndrome. Genomics 2006;87:693-703.

28. Ardigo D, Gaillard CA, Braam B. Application of leukocyte transcriptomes to assess systemic consequences of risk factors for cardiovascular disease. Clin Chem Lab Med 2007;45:1109-20.

29. Basheer R, Brown R, Ramesh V, Begum S, McCarley RW. Sleep deprivation-induced protein changes in basal forebrain: implications for synaptic plasticity. J Neurosci Res 2005;82:650-8.

30. Klein JB, Gozal D, Pierce WM, et al. Proteomic identification of a novel protein regulated in CA1 and CA3 hippocampal regions during intermittent hypoxia. Respir Physiol Neurobiol 2003;136:91-103.

31. Krishna J, Shah ZA, Merchant M, Klein JB, Gozal D. Urinary protein expression patterns in children with sleep-disordered breathing: preliminary findings. Sleep Med 2006;7:221-7.

32. Shah ZA, Jortani SA, Tauman R, Valdes R, Jr., Gozal D. Serum proteomic patterns associated with sleep-disordered breathing in children. Pediatr Res 2006;59:466-70.

33. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10:860-8.

34. Kang X, Xu Y, Wu X, et al. Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome. Clin Chem 2005;51:56-64.

35. Pawlyk AC, Ferber M, Shah A, Pack AI, Naidoo N. Proteomic analysis of the effects and interactions of sleep deprivation and aging in mouse cerebral cortex. J Neurochem 2007;103:2301-13.

36. Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers. Mol Cell Proteomics 2006;5:1760-71.

37. Meyer HE, Stuhler K. High-performance proteomics as a tool in biomarker discovery. Proteomics 2007;7 Suppl 1:18-26.

38. Sabatine MS, Liu E, Morrow DA, et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005;112:3868-75.

39. Wang C, Kong H, Guan Y, et al. Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis. Anal Chem 2005;77:4108-16.

40. Yang J, Xu G, Hong Q, et al. Discrimination of Type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profiles. J Chromatogr B Analyt Technol Biomed Life Sci 2004;813:53-8.

41. Schnackenberg LK, Beger RD. Monitoring the health to disease continuum with global metabolic profiling and systems biology. Pharmacogenomics 2006;7:1077-86.

42. Weckwerth W, Morgenthal K. Metabolomics: from pattern recognition to biological interpretation. Drug Discov Today 2005;10:1551-8.

43. Bell J. Predicting disease using genomics. Nature 2004;429:453-6.

44. Ginsburg GS, Donahue MP, Newby LK. Prospects for personalized cardiovascular medicine: the impact of genomics. J Am Coll Cardiol 2005;46:1615-27.

45. Lango H, Weedon MN. What will whole genome searches for susceptibility genes for common complex disease offer to clinical practice? J Intern Med 2008;263:16-27.

46. Arnett DK, Baird AE, Barkley RA, et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007;115:2878-901.

47. Caples SM, Gami AS, Somers VK. Obstructive sleep apnea. Ann Intern Med 2005;142:187-97.

48. Pack AI. Advances in sleep-disordered breathing. Am J Respir Crit Care Med 2006;173:7-15.

49. Barbe F, Mayoralas LR, Duran J, et al. Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness. a randomized, controlled trial. Ann Intern Med 2001;134:1015-23.

50. Thorpy MJ. The clinical use of the Multiple Sleep Latency Test. The Standards of Practice Committee of the American Sleep Disorders Association. Sleep 1992;15:268-76.

51. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986;9:519-24.

52. Littner MR, Kushida C, Wise M, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005;28:113-21.

53. Doghramji K, Mitler MM, Sangal RB, et al. A normative study of the maintenance of wakefulness test (MWT). Electroencephalogr Clin Neurophysiol 1997;103:554-62.

54. Lim J, Dinges DF. Sleep deprivation and vigilant attention. Ann N Y Acad Sci 2008;1129:305-22.

55. Dinges DF, Powell JW. Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations. Behav Res Meth Instr Comp 1985;17:652-5.

56. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5.

57. Johns MW. Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest 1993;103:30-6.

58. Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep 1992;15:376-81.

59. Kaida K, Takahashi M, Akerstedt T, et al. Validation of the Karolinska sleepiness scale against performance and EEG variables. Clin Neurophysiol 2006;117:1574-81.

60. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000;283:1829-36.

61. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ 2000;320:479-82.

62. Bixler EO, Vgontzas AN, Lin HM, et al. Association of hypertension and sleep-disordered breathing. Arch Intern Med 2000;160:2289-95.

63. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378-84.

64. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit Care Med 2002;166:159-65.

65. Peker Y, Kraiczi H, Hedner J, Loth S, Johansson A, Bende M. An independent association between obstructive sleep apnoea and coronary artery disease. Eur Respir J 1999;14:179-84.

66. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005;353:2034-41.

67. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046-53.

68. Munoz R, Duran-Cantolla J, Martinez-Vila E, et al. Severe

sleep apnea and risk of ischemic stroke in the elderly. Stroke 2006;37:2317-21.

69. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-5.

70. Ip MS, Lam KS, Ho C, Tsang KW, Lam W. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 2000;118:580-6.

71. Ciftci TU, Kokturk O, Bukan N, Bilgihan A. The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome. Cytokine 2004;28:87-91.

72. El-Solh AA, Mador MJ, Sikka P, Dhillon RS, Amsterdam D, Grant BJ. Adhesion molecules in patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest 2002;121:1541-7.

73. Barcelo A, Barbe F, Llompart E, et al. Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. Am J Med 2004;117:118-21.

74. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997;82:1313-6.

75. Imagawa S, Yamaguchi Y, Ogawa K, et al. Interleukin-6 and tumor necrosis factor-alpha in patients with obstructive sleep apnea-hypopnea syndrome. Respiration 2004;71:24-9.

76. Khalyfa A, Capdevila OS, Buazza MO, Serpero LD, Kheirandish-Gozal L, Gozal D. Genome-wide gene expression profiling in children with non-obese obstructive sleep apnea. Sleep Med 2008 Feb 6 [Epub ahead of print].

77. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:1217-39.

78. McNicholas WT, Bonsigore MR. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 2007;29:156-78.

79. Sullivan CE, Issa FG, Berthon-Jones M, Eves L. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1981;1:862-5.

80. Jenkinson C, Davies RJ, Mullins R, Stradling JR. Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet 1999;353:2100-5.

81. Giles TL, Lasserson TJ, Smith BJ, White J, Wright J, Cates CJ. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006:CD001106.

82. Meurice JC, Dore P, Paquereau J, et al. Predictive factors of long-term compliance with nasal continuous positive airway pressure treatment in sleep apnea syndrome. Chest 1994;105:429-33.

83. Weaver TE, Maislin G, Dinges DF, et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep 2007;30:711-9.

84. Effros RM, Dunning MB 3rd, Biller J, Shaker R. The promise and perils of exhaled breath condensates. Am J Physiol Lung Cell Mol Physiol 2004;287:L1073-80.

85. Ryan S, Taylor CT, McNicholas WT. Predictors of elevated nuclear factor-kappaB-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2006;174:824-30.

86. Jordan W, Cohrs S, Degner D, et al. Evaluation of oxidative stress measurements in obstructive sleep apnea syndrome. J Neural Transm 2006;113:239-54.

87. Chin K, Ohi M, Shimizu K, Nakamura T, Miyaoka F, Mishima M. Increase in bilirubin levels of patients with obstructive sleep apnea in the morning--a possible explanation of induced heme oxygenase-1. Sleep 2001;24:218-23.

88. Alberti A, Sarchielli P, Gallinella E, Floridi A, Mazzotta G, Gallai

89. V. Plasma cytokine levels in patients with obstructive sleep apnea syndrome: a preliminary study. J Sleep Res 2003;12:305-11.

89. Sonka K, Kelemen J, Kemlink D, et al. Evening and morning plasma levels of protein S100B in patients with obstructive sleep apnea. Neuro Endocrinol Lett 2007;28:575-9.

90. Carpagnano GE, Kharitonov SA, Resta O, Foschino-Barbaro MP, Gramiccioni E, Barnes PJ. Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients. Chest 2002;122:1162-7.

91. Carpagnano GE, Kharitonov SA, Resta O, Foschino-Barbaro MP, Gramiccioni E, Barnes PJ. 8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy. Chest 2003;124:1386-92.

92. Lavie L. Sleep-disordered breathing and cerebrovascular disease: a mechanistic approach. Neurol Clin 2005;23:1059-75.

93. Chiang AA. Obstructive sleep apnea and chronic intermittent hypoxia: a review. Chin J Physiol 2006;49:234-43.

94. Prabhakar NR, Kumar GK, Nanduri J, Semenza GL. ROS signaling in systemic and cellular responses to chronic intermittent hypoxia. Antioxid Redox Signal 2007;9:1397-403.

95. Semenza GL, Prabhakar NR. HIF-1-dependent respiratory, cardiovascular, and redox responses to chronic intermittent hypoxia. Antioxid Redox Signal 2007;9:1391-6.

96. Fletcher EC, Lesske J, Qian W, Miller CC 3rd, Unger T. Repetitive, episodic hypoxia causes diurnal elevation of blood pressure in rats. Hypertension 1992;19:555-61.

97. Fletcher EC, Lesske J, Behm R, Miller CC 3rd, Stauss H, Unger T. Carotid chemoreceptors, systemic blood pressure, and chronic episodic hypoxia mimicking sleep apnea. J Appl Physiol 1992;72:1978-84.

98. Lesske J, Fletcher EC, Bao G, Unger T. Hypertension caused by chronic intermittent hypoxia--influence of chemoreceptors and sympathetic nervous system. J Hypertens 1997;15:1593-603.

99. Gozal D, Row BW, Kheirandish L, et al. Increased susceptibility to intermittent hypoxia in aging rats: changes in proteasomal activity, neuronal apoptosis and spatial function. J Neurochem 2003;86:1545-52.

100. Li RC, Row BW, Gozal E, et al. Cyclooxygenase 2 and intermittent hypoxia-induced spatial deficits in the rat. Am J Respir Crit Care Med 2003;168:469-75.

101. Row BW, Goldbart A, Gozal E, Gozal D. Spatial pre-training attenuates hippocampal impairments in rats exposed to intermittent hypoxia. Neurosci Lett 2003;339:67-71.

102. Chen L, Einbinder E, Zhang Q, Hasday J, Balke CW, Scharf SM. Oxidative stress and left ventricular function with chronic intermittent hypoxia in rats. Am J Respir Crit Care Med 2005;172:915-20.

103. Kheirandish L, Row BW, Li RC, Brittian KR, Gozal D. Apolipoprotein E-deficient mice exhibit increased vulnerability to intermittent hypoxia-induced spatial learning deficits. Sleep 2005;28:1412-7.

104. Goldbart AD, Row BW, Kheirandish-Gozal L, Cheng Y, Brittian KR, Gozal D. High fat/refined carbohydrate diet enhances the susceptibility to spatial learning deficits in rats exposed to intermittent hypoxia. Brain Res 2006;1090:190-6.

105. Kumar GK, Rai V, Sharma SD, et al. Chronic intermittent hypoxia induces hypoxia-evoked catecholamine efflux in adult rat adrenal medulla via oxidative stress. J Physiol 2006;575:229-39.

106. Row BW, Kheirandish L, Cheng Y, Rowell PP, Gozal D. Impaired spatial working memory and altered choline acetyltransferase (CHAT) immunoreactivity and nicotinic receptor binding in rats exposed to intermittent hypoxia during sleep. Behav Brain Res 2007;177:308-14.

107. Zoccal DB, Bonagamba LG, Oliveira FR, Antunes-Rodrigues J,

Machado BH. Increased sympathetic activity in rats submitted to chronic intermittent hypoxia. Exp Physiol 2007;92:79-85.

108. Zhan G, Fenik P, Pratico D, Veasey SC. Inducible nitric oxide synthase in long-term intermittent hypoxia: hypersomnolence and brain injury. Am J Respir Crit Care Med 2005;171:1414-20.

109. Zhan G, Serrano F, Fenik P, et al. NADPH oxidase mediates hypersomnolence and brain oxidative injury in a murine model of sleep apnea. Am J Respir Crit Care Med 2005;172:921-9.

110. Polotsky VY, Li J, Punjabi NM, et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol (Lond) 2003;552:253-64.

111. Veasey SC, Davis CW, Fenik P, et al. Long-term intermittent hypoxia in mice: protracted hypersomnolence with oxidative injury to sleep-wake brain regions. Sleep 2004;27:194-201.

112. Xu W, Chi L, Row BW, et al. Increased oxidative stress is associated with chronic intermittent hypoxia-mediated brain cortical neuronal cell apoptosis in a mouse model of sleep apnea. Neuroscience 2004;126:313-23.

113. Peng YJ, Yuan G, Ramakrishnan D, et al. Heterozygous HIF-1alpha deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J Physiol 2006;577:705-16.

114. Phillips SA, Olson EB, Lombard JH, Morgan BJ. Chronic intermittent hypoxia alters NE reactivity and mechanics of skeletal muscle resistance arteries. J Appl Physiol 2006;100:1117-23.

115. Iiyori N, Alonso LC, Li J, et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 2007;175:851-7.

116. Savransky V, Bevans S, Nanayakkara A, et al. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol 2007;293:G871-7.

117. Yokoe T, Alonso LC, Romano LC, et al. Intermittent hypoxia reverses the diurnal glucose rhythm and causes pancreatic beta-cell replication in mice. J Physiol 2008;586:899-911.

118. Zhu Y, Fenik P, Zhan G, et al. Selective loss of catecholaminergic wake active neurons in a murine sleep apnea model. J Neurosci 2007;27:10060-71.

119. Dematteis M, Julien C, Guillermet C, et al. Intermittent hypoxia induces early functional cardiovascular remodeling in mice. Am J Respir Crit Care Med 2008;177:227-35.

120. Yuan G, Adhikary G, McCormick AA, Holcroft JJ, Kumar GK, Prabhakar NR. Role of oxidative stress in intermittent hypoxia-induced immediate early gene activation in rat PC12 cells. J Physiol 2004;557:773-83.

121. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005;112:2660-7.

122. Ryan S, McNicholas WT, Taylor CT. A critical role for p38 map kinase in NF-kappaB signaling during intermittent hypoxia/reoxygenation. Biochem Biophys Res Commun 2007;355:728-33.

123. Shan X, Chi L, Ke Y, et al. Manganese superoxide dismutase protects mouse cortical neurons from chronic intermittent hypoxia-mediated oxidative damage. Neurobiol Dis 2007;28:206-15.

124. Fletcher EC, Lesske J, Culman J, Miller CC, Unger T. Sympathetic denervation blocks blood pressure elevation in episodic hypoxia. Hypertension 1992;20:612-9.

125. Yuan G, Nanduri J, Bhasker CR, Semenza GL, Prabhakar NR. Ca2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J Biol Chem 2005;280:4321-8.

126. Toffoli S, Feron O, Raes M, Michiels C. Intermittent hypoxia changes HIF-1alpha phosphorylation pattern in endothelial cells: unravelling of a new PKA-dependent regulation of HIF-1alpha. Biochim Biophys Acta 2007;1773:1558-71.

127. Li J, Bosch-Marce M, Nanayakkara A, et al. Altered metabolic responses to intermittent hypoxia in mice with partial deficiency of hypoxia-inducible factor-1alpha. Physiol Genomics 2006;25:450-7.

128. Belaidi E, Beguin PC, Levy P, Ribuot C, Godin-Ribuot D. Prevention of HIF-1 activation and iNOS gene targeting by low-dose cadmium results in loss of myocardial hypoxic preconditioning in the rat. Am J Physiol Heart Circ Physiol 2007.

129. Rius J, Guma M, Schachtrup C, et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008;453:807-11.

130. Lam SY, Tipoe GL, Liong EC, Fung ML. Differential expressions and roles of hypoxia-inducible factor-1alpha, -2alpha and -3alpha in the rat carotid body during chronic and intermittent hypoxia. Histol Histopathol 2008;23:271-80.

131. Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep 1997;20:705-6.

132. Li J, Thorne LN, Punjabi NM, et al. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 2005;97:698-706.

133. Somers VK, Mark AL, Zavala DC, Abboud FM. Contrasting effects of hypoxia and hypercapnia on ventilation and sympathetic activity in humans. J Appl Physiol 1989;67:2101-6.

134. Somers VK, Mark AL, Zavala DC, Abboud FM. Influence of ventilation and hypocapnia on sympathetic nerve responses to hypoxia in normal humans. J Appl Physiol 1989;67:2095-100.

135. Leuenberger U, Jacob E, Sweer L, Waravdekar N, Zwillich C, Sinoway L. Surges of muscle sympathetic nerve activity during obstructive apnea are linked to hypoxemia. J Appl Physiol 1995;79:581-8.

136. Babior BM. Phagocytes and oxidative stress. Am J Med 2000;109:33-44.

137. Lavie L. Obstructive sleep apnoea syndrome - an oxidative stress disorder. Sleep Med Rev 2003;7:35-51.

138. Horner RL, Brooks D, Kozar LF, Tse S, Phillipson EA. Immediate effects of arousal from sleep on cardiac autonomic outflow in the absence of breathing in dogs. J Appl Physiol 1995;79:151-62.

139. Blasi A, Jo J, Valladares E, Morgan BJ, Skatrud JB, Khoo MC. Cardiovascular variability after arousal from sleep: time-varying spectral analysis. J Appl Physiol 2003;95:1394-404.

140. Blasi A, Jo JA, Valladares E, Juarez R, Baydur A, Khoo MC. Autonomic cardiovascular control following transient arousal from sleep: a time-varying closed-loop model. IEEE Trans Biomed Eng 2006;53:74-82.

141. Catcheside PG, Chiong SC, Mercer J, Saunders NA, McEvoy RD. Noninvasive cardiovascular markers of acoustically induced arousal from non-rapid-eye-movement sleep. Sleep 2002;25:797-804.

142. Nalivaiko E, Catcheside PG, Adams A, Jordan AS, Eckert DJ, McEvoy RD. Cardiac changes during arousals from non-REM sleep in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2007;292:R1320-7.

143. Ekstedt M, Akerstedt T, Soderstrom M. Microarousals during sleep are associated with increased levels of lipids, cortisol, and blood pressure. Psychosom Med 2004;66:925-31.

144. Bonnet MH, Berry RB, Arand DL. Metabolism during normal, fragmented, and recovery sleep. J Appl Physiol 1991;71:1112-8.

145. Bonnet MH. Effect of sleep disruption on sleep, performance, and mood. Sleep 1985;8:11-9.

146. Ayas NT, White DP, Al-Delaimy WK, et al. A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care 2003;26:380-4.

147. Andretic R, Shaw PJ. Essentials of sleep recordings in Drosophila: moving beyond sleep time. Methods Enzymol 2005;393:759-72.

148. Gangwisch JE, Heymsfield SB, Boden-Albala B, et al. Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey. Hypertension 2006;47:833-9.

149. Yu Y, Lu BS, Wang B, et al. Short sleep duration and adiposity in Chinese adolescents. Sleep 2007;30:1688-97.

150. Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. J Appl Physiol 2005;99:2008-19.

151. Dinges DF, Pack F, Williams K, et al. Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4-5 hours per night. Sleep 1997;20:267-7.

152. Van Dongen HP, Maislin G, Mullington JM, Dinges DF. The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep 2003;26:117-26.

153. Haack M, Mullington JM. Sustained sleep restriction reduces emotional and physical well-being. Pain 2005;119:56-64.

154. Casement MD, Broussard JL, Mullington JM, Press DZ. The contribution of sleep to improvements in working memory scanning speed: a study of prolonged sleep restriction. Biol Psychol 2006;72:208-12.

155. Meier-Ewert HK, Ridker PM, Rifai N, et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol 2004;43:678-83.

156. Vgontzas AN, Zoumakis E, Bixler EO, et al. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab 2004;89:2119-26.

157. Irwin MR, Wang M, Campomayor CO, Collado-Hidalgo A, Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch Intern Med 2006;166:1756-62.

158. Jain V. Clinical perspective of obstructive sleep apnea-induced cardiovascular complications. Antioxid Redox Signal 2007;9:701-10.

159. Umlauf MG, Chasens ER. Sleep disordered breathing and nocturnal polyuria: nocturia and enuresis. Sleep Med Rev 2003;7:403-11.

160. Lew RA, Baertschi AJ. Mechanisms of hypoxia-induced atrial natriuretic factor release from rat hearts. Am J Physiol 1989;257:H147-56.

161. Lin CC, Tsan KW, Lin CY. Plasma levels of atrial natriuretic factor in moderate to severe obstructive sleep apnea syndrome. Sleep 1993;16:37-9.

162. Umlauf MG, Chasens ER, Greevy RA, Arnold J, Burgio KL, Pillion DJ. Obstructive sleep apnea, nocturia and polyuria in older adults. Sleep 2004;27:139-44.

163. Krieger J, Follenius M, Sforza E, Brandenberger G, Peter JD. Effects of treatment with nasal continuous positive airway pressure on atrial natriuretic peptide and arginine vasopressin release during sleep in patients with obstructive sleep apnoea. Clin Sci (Lond) 1991;80:443-9.

164. Krieger J, Laks L, Wilcox I, et al. Atrial natriuretic peptide release during sleep in patients with obstructive sleep apnoea before and during treatment with nasal continuous positive airway pressure. Clin Sci (Lond) 1989;77:407-11.

165. Kita H, Ohi M, Chin K, et al. The nocturnal secretion of cardiac natriuretic peptides during obstructive sleep apnoea and its response to therapy with nasal continuous positive airway pressure. J Sleep Res 1998;7:199-207.

166. Yalkut D, Lee LY, Grider J, Jorgensen M, Jackson B, Ott C. Mechanism of atrial natriuretic peptide release with increased inspiratory resistance. J Lab Clin Med 1996;128:322-8.

167. Schafer H, Ehlenz K, Ewig S, et al. Atrial natriuretic peptide levels and pulmonary artery pressure awake, at exercise and asleep in obstructive sleep apnoea syndrome. J Sleep Res 1999;8:205-10.

168. Patwardhan AA, Larson MG, Levy D, et al. Obstructive sleep apnea and plasma natriuretic peptide levels in a community-based sample. Sleep 2006;29:1301-6.

169. Gjorup PH, Sadauskiene L, Wessels J, Nyvad O, Strunge B, Pedersen EB. Increased nocturnal sodium excretion in obstructive sleep apnoea. Relation to nocturnal change in diastolic blood pressure. Scand J Clin Lab Invest 2008;68:11-21.

170. Kimura K, Yamaguchi Y, Horii M, et al. ANP is cleared much faster than BNP in patients with congestive heart failure. Eur J Clin Pharmacol 2007;63:699-702.

171. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH. Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci 1986;38:1827-33.

172. Exar EN, Collop NA. The upper airway resistance syndrome. Chest 1999;115:1127-39.

173. Guilleminault C, Stoohs R, Shiomi T, Kushida C, Schnittger I. Upper airway resistance syndrome, nocturnal blood pressure monitoring, and borderline hypertension. Chest 1996;109:901-8.

174. Chen L, Scharf SM. Comparative hemodynamic effects of periodic obstructive and simulated central apneas in sedated pigs. J Appl Physiol 1997;83:485-94.

175. White SG, Fletcher EC, Miller CC, 3rd. Acute systemic blood pressure elevation in obstructive and nonobstructive breath hold in primates. J Appl Physiol 1995;79:324-30.

176. Almendros I, Carreras A, Ramirez J, Montserrat JM, Navajas D, Farre R. Upper airway collapse and reopening induce inflammation in a sleep apnoea model. Eur Respir J 2008;32:399-404.

177. Almendros I, Acerbi I, Puig F, Montserrat JM, Navajas D, Farre R. Upper-airway inflammation triggered by vibration in a rat model of snoring. Sleep 2007;30:225-7.

178. Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998;98:772-6.

179. Grassi G, Facchini A, Trevano FQ, et al. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 2005;46:321-5.

180. Waradekar NV, Sinoway LI, Zwillich CW, Leuenberger UA. Influence of treatment on muscle sympathetic nerve activity in sleep apnea. Am J Respir Crit Care Med 1996;153:1333-8.

181. Narkiewicz K, Kato M, Phillips BG, Pesek CA, Davison DE, Somers VK. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation 1999;100:2332-5.

182. Donadio V, Liguori R, Vetrugno R, et al. Daytime sympathetic hyperactivity in OSAS is related to excessive daytime sleepiness. J Sleep Res 2007;16:327-32.

183. Goldstein DS, Eisenhofer G, Kopin IJ. Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 2003;305:800-11.

184. Fletcher EC, Miller J, Schaaf JW, Fletcher JG. Urinary catecholamines before and after tracheostomy in patients with obstructive sleep apnea and hypertension. Sleep 1987;10:35-44.

185. McArdle N, Hillman D, Beilin L, Watts G. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med 2007;175:190-5.

186. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2007;176:706-12.

187. Heitmann J, Ehlenz K, Penzel T, et al. Sympathetic activity is reduced by nCPAP in hypertensive obstructive sleep apnea patients. Eur Respir J 2004;23:255-62.

188. Mansfield DR, Gollogly NC, Kaye DM, Richardson M, Bergin P, Naughton MT. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med 2004;169:361-6.

189. Ziegler MG, Mills PJ, Loredo JS, Ancoli-Israel S, Dimsdale JE. Effect of continuous positive airway pressure and placebo treat-

ment on sympathetic nervous activity in patients with obstructive sleep apnea. Chest 2001;120:887-93.

190. Hedner J, Darpo B, Ejnell H, Carlson J, Caidahl K. Reduction in sympathetic activity after long-term CPAP treatment in sleep apnoea: cardiovascular implications. Eur Respir J 1995;8:222-9.

191. Minemura H, Akashiba T, Yamamoto H, Akahoshi T, Kosaka N, Horie T. Acute effects of nasal continuous positive airway pressure on 24-hour blood pressure and catecholamines in patients with obstructive sleep apnea. Intern Med 1998;37:1009-13.

192. Sukegawa M, Noda A, Sugiura T, et al. Assessment of continuous positive airway pressure treatment in obstructive sleep apnea syndrome using 24-hour urinary catecholamines. Clin Cardiol 2005;28:519-22.

193. Marrone O, Riccobono L, Salvaggio A, Mirabella A, Bonanno A, Bonsignore MR. Catecholamines and blood pressure in obstructive sleep apnea syndrome. Chest 1993;103:722-7.

194. Grunstein RR, Stewart DA, Lloyd H, Akinci M, Cheng N, Sullivan CE. Acute withdrawal of nasal CPAP in obstructive sleep apnea does not cause a rise in stress hormones. Sleep 1996;19:774-82.

195. Phillips CL, Yang Q, Williams A, et al. The effect of short-term withdrawal from continuous positive airway pressure therapy on sympathetic activity and markers of vascular inflammation in subjects with obstructive sleep apnoea. J Sleep Res 2007;16:217-25.

196. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995;96:1897-904.

197. Wieber SJ. The cardiac consequences of the obstructive sleep apnea-hypopnea syndrome. Mt Sinai J Med 2005;72:10-2.

198. Marcus C, Ehren H, Bolme P, Arner P. Regulation of lipolysis during the neonatal period. Importance of thyrotropin. J Clin Invest 1988;82:1793-7.

199. Hucking K, Hamilton-Wessler M, Ellmerer M, Bergman RN. Burst-like control of lipolysis by the sympathetic nervous system in vivo. J Clin Invest 2003;111:257-64.

200. Coppack SW, Jensen MD, Miles JM. In vivo regulation of lipolysis in humans. J Lipid Res 1994;35:177-93.

201. Nguyen MT, Favelyukis S, Nguyen AK, et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007;282:35279-92.

202. Nguyen MT, Satoh H, Favelyukis S, et al. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 2005;280:35361-71.

203. Kim SP, Catalano KJ, Hsu IR, Chiu JD, Richey JM, Bergman RN. Nocturnal free fatty acids are uniquely elevated in the longitudinal development of diet-induced insulin resistance and hyperinsulinemia. Am J Physiol Endocrinol Metab 2007;292:E1590-8.

204. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000;11:351-6.

205. Makino S, Handa H, Suzukawa K, et al. Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance. Clin Endocrinol (Oxf) 2006;64:12-9.

206. Barcelo A, Miralles C, Barbe F, Vila M, Pons S, Agusti AG. Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J 2000;16:644-7.

207. Lavie L, Vishnevsky A, Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 2004;27:123-8.

208. Yamauchi M, Nakano H, Maekawa J, et al. Oxidative stress in obstructive sleep apnea. Chest 2005;127:1674-9.

209. Minoguchi K, Yokoe T, Tanaka A, et al. Association between lipid peroxidation and inflammation in obstructive sleep apnoea. Eur Respir J 2006;28:378-85.

210. Morrow JD, Roberts LJ. The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease. Am J Respir Crit Care Med 2002;166:S25-30.

211. Halliwell B, Whiteman M. Measuring reactive species and oxida-

tive damage in vivo and in cell culture: how should you do it and what do the results mean? Br J Pharmacol 2004;142:231-55.

212. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 2006;52:601-23.

213. Kadiiska MB, Gladen BC, Baird DD, et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 2005;38:698-710.

214. Svatikova A, Wolk R, Lerman LO, et al. Oxidative stress in obstructive sleep apnoea. Eur Heart J 2005;26:2435-9.

215. Ozturk L, Mansour B, Yuksel M, Yalcin AS, Celikoglu F, Gokhan N. Lipid peroxidation and osmotic fragility of red blood cells in sleep-apnea patients. Clin Chim Acta 2003;332:83-8.

216. Alzoghaibi MA, Bahammam AS. Lipid peroxides, superoxide dismutase and circulating IL-8 and GCP-2 in patients with severe obstructive sleep apnea: a pilot study. Sleep Breath 2005;9:119-26.

217. Yan W, Byrd GD, Ogden MW. Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS. J Lipid Res 2007;48:1607-17.

218. Basu S. Metabolism of 8-iso-prostaglandin F2alpha. FEBS Lett 1998;428:32-6.

219. Griffiths HR, Moller L, Bartosz G, et al. Biomarkers. Mol Aspects Med 2002;23:101-208.

220. Morrow JD, Zackert WE, Yang JP, et al. Quantification of the major urinary metabolite of 15-F2t-isoprostane (8-iso-PGF2alpha) by a stable isotope dilution mass spectrometric assay. Anal Biochem 1999;269:326-31.

221. Liu H, Liu J, Xiong S, Shen G, Zhang Z, Xu Y. The change of interleukin-6 and tumor necrosis factor in patients with obstructive sleep apnea syndrome. J Tongji Med Univ 2000;20:200-2.

222. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002;105:2462-4.

223. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003;107:1129-34.

224. Minoguchi K, Tazaki T, Yokoe T, et al. Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome. Chest 2004;126:1473-9.

225. Minoguchi K, Yokoe T, Tazaki T, et al. Increased carotid intima-media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 2005;172:625-30.

226. Kobayashi K, Nishimura Y, Shimada T, et al. Effect of continuous positive airway pressure on soluble CD40 ligand in patients with obstructive sleep apnea syndrome. Chest 2006;129:632-7.

227. Bravo Mde L, Serpero LD, Barcelo A, Barbe F, Agusti A, Gozal D. Inflammatory proteins in patients with obstructive sleep apnea with and without daytime sleepiness. Sleep Breath 2007;11:177-85.

228. Guilleminault C, Kirisoglu C, Ohayon MM. C-reactive protein and sleep-disordered breathing. Sleep 2004;27:1507-11.

229. Sharma SK, Mishra HK, Sharma H, et al. Obesity, and not obstructive sleep apnea, is responsible for increased serum hs-CRP levels in patients with sleep-disordered breathing in Delhi. Sleep Med 2008;9:149-56.

230. Roytblat L, Rachinsky M, Fisher A, et al. Raised interleukin-6 levels in obese patients. Obes Res 2000;8:673-5.

231. Mehra R, Storfer-Isser A, Kirchner HL, et al. Soluble interleukin 6 receptor: A novel marker of moderate to severe sleep-related breathing disorder. Arch Intern Med 2006;166:1725-31.

232. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151-8.

233. Hayashi M, Fujimoto K, Urushibata K, Takamizawa A, Kinoshita

O, Kubo K. Hypoxia-sensitive molecules may modulate the development of atherosclerosis in sleep apnoea syndrome. Respirology 2006;11:24-31.

234. Paulsen FP, Steven P, Tsokos M, et al. Upper airway epithelial structural changes in obstructive sleep-disordered breathing. Am J Respir Crit Care Med 2002;166:501-9.

235. Boyd JH, Petrof BJ, Hamid Q, Fraser R, Kimoff RJ. Upper airway muscle inflammation and denervation changes in obstructive sleep apnea. Am J Respir Crit Care Med 2004;170:541-6.

236. Sabato R, Guido P, Salerno FG, Resta O, Spanevello A, Barbaro MP. Airway inflammation in patients affected by obstructive sleep apnea. Monaldi Arch Chest Dis 2006;65:102-5.

237. Exley AR, Cohen J. Optimal collection of blood samples for the measurement of tumor necrosis factor alpha. Cytokine 1990;2:353-6.

238. Flower L, Ahuja RH, Humphries SE, Mohamed-Ali V. Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-alpha and leptin. Cytokine 2000;12:1712-6.

239. Seiler W, Muller H, Hiemke C. Interleukin-6 in plasma collected with an indwelling cannula reflects local, not systemic, concentrations. Clin Chem 1994;40:1778-9.

240. Gudmundsson A, Ershler WB, Goodman B, Lent SJ, Barczi S, Carnes M. Serum concentrations of interleukin-6 are increased when sampled through an indwelling venous catheter. Clin Chem 1997;43:2199-201.

241. Haack M, Kraus T, Schuld A, Dalal M, Koethe D, Pollmacher T. Diurnal variations of interleukin-6 plasma levels are confounded by blood drawing procedures. Psychoneuroendocrinology 2002;27:921-31.

242. Haack M, Reichenberg A, Kraus T, Schuld A, Yirmiya R, Pollmacher T. Effects of an intravenous catheter on the local production of cytokines and soluble cytokine receptors in healthy men. Cytokine 2000;12:694-8.

243. Bekri S, Gual P, Anty R, et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006;131:788-96.

244. Bae SK, Kim SR, Kim JG, et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett 2006;580:4105-13.

245. Segawa K, Fukuhara A, Hosogai N, et al. Visfatin in adipocytes is upregulated by hypoxia through HIF1alpha-dependent mechanism. Biochem Biophys Res Commun 2006;349:875-82.

246. Bo S, Ciccone G, Durazzo M, et al. Efficacy of antioxidant treatment in reducing resistin serum levels: a randomized study. PLoS Clin Trials 2007;2:e17.

247. Kamigaki M, Sakaue S, Tsujino I, et al. Oxidative stress provokes atherogenic changes in adipokine gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2006;339:624-32.

248. Soares AF, Guichardant M, Cozzone D, et al. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic Biol Med 2005;38:882-9.

249. Sarraf P, Frederich RC, Turner EM, et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med 1997;185:171-5.

250. Grunfeld C, Zhao C, Fuller J, et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 1996;97:2152-7.

251. Faggioni R, Fantuzzi G, Fuller J, Dinarello CA, Feingold KR, Grunfeld C. IL-1 beta mediates leptin induction during inflammation. Am J Physiol 1998;274:R204-8.

252. Hector J, Schwarzloh B, Goehring J, et al. TNF-alpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 2007;39:250-5.

253. Fasshauer M, Kralisch S, Klier M, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003;301:1045-50.

254. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004;1:e45.

255. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005;174:5789-95.

256. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Tumor necrosis factor alpha is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2001;288:1027-31.

257. Nowell MA, Richards PJ, Fielding CA, et al. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2006;54:2084-95.

258. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003;285:E527-33.

259. Shojima N, Sakoda H, Ogihara T, et al. Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 2002;51:1737-44.

260. Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 1999;66:876-88.

261. Roebuck KA. Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB. Int J Mol Med 1999;4:223-30.

262. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007;18:313-25.

263. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin--the classical, resistin--the controversical, adiponectin--the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005;19:525-46.

264. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037-44.

265. Hashimoto T, Kihara M, Imai N, et al. Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol 2007;171:1705-12.

266. Kim SR, Bae YH, Bae SK, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 2008;1783:886-95.

267. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6.

268. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461-3.

269. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005;102:10610-5.

270. Daviaud D, Boucher J, Gesta S, et al. TNFalpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J 2006;20:1528-30.

271. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-58.

272. Wen Y, Wang HW, Wu J, Lu HL, Hu XF, Cianflone K. Effects of fatty acid regulation on visfatin gene expression in adipocytes. Chin Med J (Engl) 2006;119:1701-8.

273. Yildiz BO, Suchard MA, Wong ML, McCann SM, Licinio J. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci U S A 2004;101:10434-9.

274. Shea SA, Hilton MF, Orlova C, Ayers RT, Mantzoros CS. Inde-

pendent circadian and sleep/wake regulation of adipokines and glucose in humans. J Clin Endocrinol Metab 2005;90:2537-44.

275. Farooqi IS, Bullmore E, Keogh J, Gillard J, O'Rahilly S, Fletcher PC. Leptin regulates striatal regions and human eating behavior. Science 2007;317:1355.

276. Alam I, Lewis K, Stephens JW, Baxter JN. Obesity, metabolic syndrome and sleep apnoea: all pro-inflammatory states. Obes Rev 2006;8:119-27.

277. Otero M, Lago R, Gomez R, et al. Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford) 2006;45:944-50.

278. Sanna V, Di Giacomo A, La Cava A, et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest 2003;111:241-50.

279. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002;110:1093-103.

280. Zhao Y, Sun R, You L, Gao C, Tian Z. Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines. Biochem Biophys Res Commun 2003;300:247-52.

281. Raso GM, Pacilio M, Esposito E, Coppola A, Di Carlo R, Meli R. Leptin potentiates IFN-gamma-induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A.1. Br J Pharmacol 2002;137:799-804.

282. Zarkesh-Esfahani H, Pockley G, Metcalfe RA, et al. High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol 2001;167:4593-9.

283. Bravo PE, Morse S, Borne DM, Aguilar EA, Reisin E. Leptin and hypertension in obesity. Vasc Health Risk Manag 2006;2:163-9.

284. Bullo M, Garcia-Lorda P, Megias I, Salas-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2003;11:525-31.

285. Bullo M, Garcia-Lorda P, Salas-Salvado J. Plasma soluble tumor necrosis factor alpha receptors and leptin levels in normal-weight and obese women: effect of adiposity and diabetes. Eur J Endocrinol 2002;146:325-31.

286. Ciccone M, Vettor R, Pannacciulli N, et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 2001;25:805-10.

287. Schafer K, Halle M, Goeschen C, et al. Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol 2004;24:112-7.

288. Paolisso G, Tagliamonte MR, Galderisi M, et al. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men. Hypertension 1999;34:1047-52.

289. de Courten M, Zimmet P, Hodge A, et al. Hyperleptinaemia: the missing link in the, metabolic syndrome? Diabet Med 1997;14:200-8.

290. Wabitsch M, Jensen PB, Blum WF, et al. Insulin and cortisol promote leptin production in cultured human fat cells. Diabetes 1996;45:1435-8.

291. Russell CD, Petersen RN, Rao SP, et al. Leptin expression in adipose tissue from obese humans: depot-specific regulation by insulin and dexamethasone. Am J Physiol 1998;275:E507-15.

292. Wang J, Obici S, Morgan K, Barzilai N, Feng Z, Rossetti L. Overfeeding rapidly induces leptin and insulin resistance. Diabetes 2001;50:2786-91.

293. Muller G, Ertl J, Gerl M, Preibisch G. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem 1997;272:10585-93.

294. Chinookoswong N, Wang JL, Shi ZQ. Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes 1999;48:1487-92.

295. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401:73-6.

296. Phillips BG, Kato M, Narkiewicz K, Choe I, Somers VK. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am J Physiol Heart Circ Physiol 2000;279:H234-7.

297. Tatsumi K, Kasahara Y, Kurosu K, Tanabe N, Takiguchi Y, Kuriyama T. Sleep oxygen desaturation and circulating leptin in obstructive sleep apnea-hypopnea syndrome. Chest 2005;127:716-21.

298. Barcelo A, Barbe F, Llompart E, et al. Neuropeptide Y and leptin in patients with obstructive sleep apnea syndrome: role of obesity. Am J Respir Crit Care Med 2005;171:183-7.

299. Chin K, Shimizu K, Nakamura T, et al. Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation 1999;100:706-12.

300. Shimizu K, Chin K, Nakamura T, et al. Plasma leptin levels and cardiac sympathetic function in patients with obstructive sleep apnoea-hypopnoea syndrome. Thorax 2002;57:429-34.

301. Harsch IA, Konturek PC, Koebnick C, et al. Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. Eur Respir J 2003;22:251-7.

302. Trenell MI, Ward JA, Yee BJ, et al. Influence of constant positive airway pressure therapy on lipid storage, muscle metabolism and insulin action in obese patients with severe obstructive sleep apnoea syndrome. Diabetes Obes Metab 2007;9:679-87.

303. Harsch IA, Schahin SP, Bruckner K, et al. The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes. Respiration 2004;71:252-9.

304. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697-703.

305. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996;120:803-12.

306. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001;98:2005-10.

307. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-53.

308. Masserini B, Morpurgo PS, Donadio F, et al. Reduced levels of adiponectin in sleep apnea syndrome. J Endocrinol Invest 2006;29:700-5.

309. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.

310. Shin MJ, Lee JH, Jang Y, et al. Insulin resistance, adipokines, and oxidative stress in nondiabetic, hypercholesterolemic patients: leptin as an 8-epi-prostaglandin F2alpha determinant. Metabolism 2006;55:918-22.

311. Tan KC, Xu A, Chow WS, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004;89:765-9.

312. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-7.

313. Masaki T, Chiba S, Tatsukawa H, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004;40:177-84.

314. Ajuwon KM, Spurlock ME. Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPAR-gamma2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 2005;288:R1220-5.

315. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived

315. plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-301.

316. Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004;316:924-9.

317. Zhang XL, Yin KS, Wang H, Su S. Serum adiponectin levels in adult male patients with obstructive sleep apnea hypopnea syndrome. Respiration 2006;73:73-7.

318. Nakagawa Y, Kishida K, Kihara S, et al. Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome. Am J Physiol Endocrinol Metab 2008;294:E778-84.

319. Wolk R, Svatikova A, Nelson CA, et al. Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep apnea. Obes Res 2005;13:186-90.

320. Zhang XL, Yin KS, Li C, Jia EZ, Li YQ, Gao ZF. Effect of continuous positive airway pressure treatment on serum adiponectin level and mean arterial pressure in male patients with obstructive sleep apnea syndrome. Chin Med J (Engl) 2007;120:1477-81.

321. Harsch IA, Wallaschofski H, Koebnick C, et al. Adiponectin in patients with obstructive sleep apnea syndrome: course and physiological relevance. Respiration 2004;71:580-6.

322. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.

323. Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003;300:472-6.

324. Fain JN, Cheema PS, Bahouth SW, Lloyd Hiler M. Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun 2003;300:674-8.

325. Yura S, Sagawa N, Itoh H, et al. Resistin is expressed in the human placenta. J Clin Endocrinol Metab 2003;88:1394-7.

326. Minn AH, Patterson NB, Pack S, et al. Resistin is expressed in pancreatic islets. Biochem Biophys Res Commun 2003;310:641-5.

327. Anderson PD, Mehta NN, Wolfe ML, et al. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab 2007;92:2272-9.

328. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003;111:225-30.

329. Moon B, Kwan JJ, Duddy N, Sweeney G, Begum N. Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation. Am J Physiol Endocrinol Metab 2003;285:E106-15.

330. Palanivel R, Maida A, Liu Y, Sweeney G. Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia 2006;49:183-90.

331. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111:932-9.

332. Savage DB, Sewter CP, Klenk ES, et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001;50:2199-202.

333. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004;27:2450-7.

334. Senolt L, Housa D, Vernerova Z, et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007;66:458-63.

335. Rajala MW, Lin Y, Ranalletta M, et al. Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-alpha in adipose tissue. Mol Endocrinol 2002;16:1920-30.

336. Burnett MS, Lee CW, Kinnaird TD, et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005;182:241-8.

337. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003;108:736-40.

338. Harsch IA, Koebnick C, Wallaschofski H, et al. Resistin levels in patients with obstructive sleep apnoea syndrome--the link to subclinical inflammation? Med Sci Monit 2004;10:CR510-5.

339. Yamamoto Y, Fujiuchi S, Hiramatsu M, et al. Resistin is closely related to systemic inflammation in obstructive sleep apnea. Respiration 2008;76:377-85.

340. Tauman R, Serpero LD, Capdevila OS, et al. Adipokines in children with sleep disordered breathing. Sleep 2007;30:443-9.

341. Kanbay A, Hasanoglu HC. A new prognostic marker for obstructive sleep apnea: hepcidin. Med Hypotheses 2007;69:1381-2.

342. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:2292-301.

343. Sawa Y, Sugimoto Y, Ueki T, et al. Effects of TNF-alpha on leukocyte adhesion molecule expressions in cultured human lymphatic endothelium. J Histochem Cytochem 2007;55:721-33.

344. Sawa Y, Ueki T, Hata M, et al. LPS-induced IL-6, IL-8, VCAM-1, and ICAM-1 expression in human lymphatic endothelium. J Histochem Cytochem 2008;56:97-109.

345. Kalogeris TJ, Kevil CG, Laroux FS, Coe LL, Phifer TJ, Alexander JS. Differential monocyte adhesion and adhesion molecule expression in venous and arterial endothelial cells. Am J Physiol 1999;276:L9-L19.

346. Elangbam CS, Qualls CW, Jr., Dahlgren RR. Cell adhesion molecules--update. Vet Pathol 1997;34:61-73.

347. Htoo AK, Greenberg H, Tongia S, et al. Activation of nuclear factor kappaB in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath 2006;10:43-50.

348. Ohga E, Nagase T, Tomita T, et al. Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol 1999;87:10-4.

349. Ohga E, Tomita T, Wada H, Yamamoto H, Nagase T, Ouchi Y. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol 2003;94:179-84.

350. Ursavas A, Karadag M, Rodoplu E, Yilmaztepe A, Oral HB, Gozu RO. Circulating ICAM-1 and VCAM-1 levels in patients with obstructive sleep apnea syndrome. Respiration 2007;74:525-32.

351. Chin K, Nakamura T, Shimizu K, Mishima M, Miyasaka M, Ohi M. Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. Am J Med 2000;109:562-7.

352. Schroder M, Kaufman RJ. ER stress and the unfolded protein response. Mutat Res 2005;569:29-63.

353. Magagnin MG, Sergeant K, van den Beucken T, et al. Proteomic analysis of gene expression following hypoxia and reoxygenation reveals proteins involved in the recovery from endoplasmic reticulum and oxidative stress. Radiother Oncol 2007;83:340-5.

354. Thuerauf DJ, Marcinko M, Gude N, Rubio M, Sussman MA, Glembotski CC. Activation of the unfolded protein response in infarcted mouse heart and hypoxic cultured cardiac myocytes. Circ Res 2006;99:275-82.

355. Feng B, Yao PM, Li Y, et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol 2003;5:781-92.

356. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457-61.

357. Boden G, Duan X, Homko C, et al. Increase in Endoplasmic Reticulum (ER) Stress Related Proteins and Genes in Adipose Tissue of Obese, Insulin Resistant Individuals. Diabetes 2008;57:2438-44.

358. Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun

NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2005;54 Suppl 2:S73-8.

359. Boden G, Duan X, Homko C, et al. Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes 2008;57:2438-44.

360. Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 2006;6:45-54.

361. Zhu Y, Fenik P, Zhan G, Sanfillipo-Cohn B, Naidoo N, Veasey SC. Eif-2a protects brainstem motoneurons in a murine model of sleep apnea. J Neurosci 2008;28:2168-78.

362. Naidoo N, Casiano V, Cater J, Zimmerman J, Pack AI. A role for the molecular chaperone protein BiP/GRP78 in Drosophila sleep homeostasis. Sleep 2007;30:557-65.

363. Naidoo N, Giang W, Galante RJ, Pack AI. Sleep deprivation induces the unfolded protein response in mouse cerebral cortex. J Neurochem 2005;92:1150-7.

364. Cirelli C, Tononi G. Gene expression in the brain across the sleep-waking cycle. Brain Res 2000;885:303-21.

365. Jones S, Pfister-Genskow M, Benca RM, Cirelli C. Molecular correlates of sleep and wakefulness in the brain of the white-crowned sparrow. J Neurochem 2008;105:46-62.

366. Shaw PJ, Cirelli C, Greenspan RJ, Tononi G. Correlates of sleep and waking in Drosophila melanogaster. Science 2000;287:1834-7.

367. Terao A, Wisor JP, Peyron C, et al. Gene expression in the rat brain during sleep deprivation and recovery sleep: an Affymetrix GeneChip study. Neuroscience 2006;137:593-605.

368. Shinohara E, Kihara S, Yamashita S, et al. Visceral fat accumulation as an important risk factor for obstructive sleep apnoea syndrome in obese subjects. J Intern Med 1997;241:11-8.

369. Grunstein R, Wilcox I, Yang TS, Gould Y, Hedner J. Snoring and sleep apnoea in men: association with central obesity and hypertension. Int J Obes Relat Metab Disord 1993;17:533-40.

370. Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA 2004;291:2013-6.

371. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000;284:3015-21.

372. Frey WC, Pilcher J. Obstructive sleep-related breathing disorders in patients evaluated for bariatric surgery. Obes Surg 2003;13:676-83.

373. Hoffstein V, Mateika S. Differences in abdominal and neck circumferences in patients with and without obstructive sleep apnoea. Eur Respir J 1992;5:377-81.

374. Millman RP, Carlisle CC, McGarvey ST, Eveloff SE, Levinson PD. Body fat distribution and sleep apnea severity in women. Chest 1995;107:362-6.

375. Catheline JM, Bihan H, Le Quang T, et al. Preoperative cardiac and pulmonary assessment in bariatric surgery. Obes Surg 2008;18:271-7.

376. Hallowell PT, Stellato TA, Schuster M, et al. Potentially life-threatening sleep apnea is unrecognized without aggressive evaluation. Am J Surg 2007;193:364-7.

377. Lee YH, Johan A, Wong KK, Edwards N, Sullivan C. Prevalence and risk factors for obstructive sleep apnea in a multiethnic population of patients presenting for bariatric surgery in Singapore. Sleep Med 2008; Mar 31 [Epub ahead of print].

378. Daltro C, Gregorio PB, Alves E, et al. Prevalence and severity of sleep apnea in a group of morbidly obese patients. Obes Surg 2007;17:809-14.

379. Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 2007;120:S12-8.

380. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9.

381. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-80.

382. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86:713-8.

383. Harsch IA, Schahin SP, Radespiel-Troger M, et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004;169:156-62.

384. Brooks B, Cistulli PA, Borkman M, et al. Obstructive sleep apnea in obese noninsulin-dependent diabetic patients: effect of continuous positive airway pressure treatment on insulin responsiveness. J Clin Endocrinol Metab 1994;79:1681-5.

385. Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 2007;50:417-23.

386. Haentjens P, Van Meerhaeghe A, Moscariello A, et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med 2007;167:757-64.

387. Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med 2001;163:344-8.

388. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002;359:204-10.

389. Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003;107:68-73.

390. Logan AG, Tkacova R, Perlikowski SM, et al. Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. Eur Respir J 2003;21:241-7.

391. Babu AR, Herdegen J, Fogelfeld L, Shott S, Mazzone T. Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. Arch Intern Med 2005;165:447-52.

392. West SD, Nicoll DJ, Wallace TM, Matthews DR, Stradling JR. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007;62:969-74.

393. Eikelis N, Esler M. The neurobiology of human obesity. Exp Physiol 2005;90:673-82.

394. Tentolouris N, Liatis S, Katsilambros N. Sympathetic system activity in obesity and metabolic syndrome. Ann N Y Acad Sci 2006;1083:129-52.

395. Vincent HK, Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond) 2006;30:400-18.

396. Vincent HK, Innes KE, Vincent KR. Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. Diabetes Obes Metab 2007;9:813-39.

397. Clement K, Langin D. Regulation of inflammation-related genes in human adipose tissue. J Intern Med 2007;262:422-30.

398. Haffner SM. Abdominal adiposity and cardiometabolic risk: do we have all the answers? Am J Med 2007;120:S10-6.

399. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.

400. Chen J, Wildman RP, Hamm LL, et al. Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2004;27:2960-5.

401. Bitar MS, Al-Saleh E, Al-Mulla F. Oxidative stress--mediated alterations in glucose dynamics in a genetic animal model of type II diabetes. Life Sci 2005;77:2552-73.

402. Ge X, Yu Q, Qi W, Shi X, Zhai Q. Chronic insulin treatment

causes insulin resistance in 3T3-L1 adipocytes through oxidative stress. Free Radic Res 2008;42:582-91.

403. Ogihara T, Asano T, Katagiri H, et al. Oxidative stress induces insulin resistance by activating the nuclear factor-kappa B pathway and disrupting normal subcellular distribution of phosphatidylinositol 3-kinase. Diabetologia 2004;47:794-805.

404. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993;21:618-23.

405. Lembo G, Rendina V, Iaccarino G, Lamenza F, Volpe M, Trimarco B. Insulin reduces reflex forearm sympathetic vasoconstriction in healthy humans. Hypertension 1993;21:1015-9.

406. Mooney RA, Senn J, Cameron S, et al. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 2001;276:25889-93.

407. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006;368:666-78.

408. Kim SK, Kim HJ, Hur KY, et al. Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but also risks of cardiovascular and metabolic diseases. Am J Clin Nutr 2004;79:593-9.

409. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007;116:39-48.

410. Rosito GA, Massaro JM, Hoffmann U, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 2008;117:605-13.

411. Onat A, Avci GS, Barlan MM, Uyarel H, Uzunlar B, Sansoy V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord 2004;28:1018-25.

412. Pascot A, Despres JP, Lemieux I, et al. Contribution of visceral obesity to the deterioration of the metabolic risk profile in men with impaired glucose tolerance. Diabetologia 2000;43:1126-35.

413. Frayn KN. Visceral fat and insulin resistance--causative or correlative? Br J Nutr 2000;83 Suppl 1:S71-7.

414. Carmelli D, Swan GE, Bliwise DL. Relationship of 30-year changes in obesity to sleep-disordered breathing in the Western Collaborative Group Study. Obes Res 2000;8:632-7.

415. Barcelo A, Barbe F, de la Pena M, et al. Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. Eur Respir J 2006;27:756-60.

416. Jurado-Gamez B, Martin-Malo A, Alvarez-Lara MA, Munoz L, Cosano A, Aljama P. Sleep disorders are underdiagnosed in patients on maintenance hemodialysis. Nephron Clin Pract 2007;105:c35-42.

417. Santamaria J, Iranzo A, Ma Montserrat J, de Pablo J. Persistent sleepiness in CPAP treated obstructive sleep apnea patients: evaluation and treatment. Sleep Med Rev 2007;11:195-207.

418. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004;15:2792-800.

419. Rankinen T, Kim SY, Perusse L, Despres JP, Bouchard C. The prediction of abdominal visceral fat level from body composition and anthropometry: ROC analysis. Int J Obes Relat Metab Disord 1999;23:801-9.

420. Despres JP. Cardiovascular disease under the influence of excess visceral fat. Crit Pathw Cardiol 2007;6:51-9.

421. Sinski M, Lewandowski J, Abramczyk P, Narkiewicz K, Gaciong Z. Why study sympathetic nervous system? J Physiol Pharmacol 2006;57 Suppl 11:79-92.

422. Watson AM, Hood SG, May CN. Mechanisms of sympathetic activation in heart failure. Clin Exp Pharmacol Physiol 2006;33:1269-74.

423. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-81.

424. Das UN. Hypertension as a low-grade systemic inflammatory condition that has its origins in the perinatal period. J Assoc Physicians India 2006;54:133-42.

425. Di Napoli M, Papa F. Inflammation, blood pressure, and stroke: an opportunity to target primary prevention? Curr Hypertens Rep 2005;7:44-51.

426. Pietropaolo M, Barinas-Mitchell E, Kuller LH. The heterogeneity of diabetes: unraveling a dispute: is systemic inflammation related to islet autoimmunity? Diabetes 2007;56:1189-97.

427. Duncan BB, Schmidt MI. The epidemiology of low-grade chronic systemic inflammation and type 2 diabetes. Diabetes Technol Ther 2006;8:7-17.

428. Wu TL, Chang PY, Tsao KC, Sun CF, Wu LL, Wu JT. A panel of multiple markers associated with chronic systemic inflammation and the risk of atherogenesis is detectable in asthma and chronic obstructive pulmonary disease. J Clin Lab Anal 2007;21:367-71.

429. Silvestri M, Bontempelli M, Giacomelli M, et al. High serum levels of tumour necrosis factor-alpha and interleukin-8 in severe asthma: markers of systemic inflammation? Clin Exp Allergy 2006;36:1373-81.

430. Yang SR, Chida AS, Bauter MR, et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol 2006;291:L46-57.

431. Andrews JO, Tingen MS. The effect of smoking, smoking cessation, and passive smoke exposure on common laboratory values in clinical settings: a review of the evidence. Crit Care Nurs Clin North Am 2006;18:63-9, xii.

432. van der Vaart H, Postma DS, Timens W, ten Hacken NH. Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax 2004;59:713-21.

433. Piconi L, Quagliaro L, Ceriello A. Oxidative stress in diabetes. Clin Chem Lab Med 2003;41:1144-9.

434. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003;17:24-38.

435. Kaneto H, Matsuoka TA, Katakami N, et al. Oxidative Stress and the JNK pathway are involved in the development of type 1 and type 2 diabetes. Curr Mol Med 2007;7:674-86.

436. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest 2007;131:1557-66.

437. Schleicher E, Friess U. Oxidative stress, AGE, and atherosclerosis. Kidney Int Suppl 2007:S17-26.

438. Yu BP, Chung HY. Adaptive mechanisms to oxidative stress during aging. Mech Ageing Dev 2006;127:436-43.

439. Afonso V, Champy R, Mitrovic D, Collin P, Lomri A. Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine 2007;74:324-9.

440. Mancia G, Bousquet P, Elghozi JL, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007;25:909-20.

441. Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002;165:670-6.

442. Parish JM, Adam T, Facchiano L. Relationship of metabolic syndrome and obstructive sleep apnea. J Clin Sleep Med 2007;3:467-72.

443. Jordan W, Berger C, Cohrs S, et al. CPAP-therapy effectively lowers serum homocysteine in obstructive sleep apnea syndrome. J Neural Transm 2004;111:683-9.

444. Polidori MC, Stahl W, Eichler O, Niestroj I, Sies H. Profiles of antioxidants in human plasma. Free Radic Biol Med 2001;30:456-62.

445. Yu BP. Cellular defenses against damage from reactive oxygen species. Physiol Rev 1994;74:139-62.

446. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004;36:1-9.

447. Cao G, Prior RL. Comparison of different analytical methods for assessing total antioxidant capacity of human serum. Clin Chem 1998;44:1309-15.

448. Hernandez C, Abreu J, Abreu P, Castro A, Jimenez A. Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP. Eur Respir J 2007;30:496-500.

449. Ulfberg J, Micic S, Strom J. Afternoon serum-melatonin in sleep disordered breathing. J Intern Med 1998;244:163-8.

450. van Exel E, Gussekloo J, de Craen AJ, Frolich M, Bootsma-Van Der Wiel A, Westendorp RG. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 2002;51:1088-92.

451. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.

452. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999;85:e17-24.

453. Pinderski Oslund LJ, Hedrick CC, Olvera T, et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999;19:2847-53.

454. Kim HJ, Higashimori T, Park SY, et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004;53:1060-7.

455. Gozal D, Serpero LD, Sans Capdevila O, Kheirandish-Gozal L. Systemic inflammation in non-obese children with obstructive sleep apnea. Sleep Med 2008;62:489-94.

456. Dyugovskaya L, Lavie P, Lavie L. Lymphocyte activation as a possible measure of atherosclerotic risk in patients with sleep apnea. Ann N Y Acad Sci 2005;1051:340-50.

457. Grote L, Kraiczi H, Hedner J. Reduced alpha- and beta(2)-adrenergic vascular response in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2000;162:1480-7.

458. Mills PJ, Kennedy BP, Loredo JS, Dimsdale JE, Ziegler MG. Effects of nasal continuous positive airway pressure and oxygen supplementation on norepinephrine kinetics and cardiovascular responses in obstructive sleep apnea. J Appl Physiol 2006;100:343-8.

459. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008;40:189-97.

460. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007;357:443-53.

461. Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007;316:1341-5.

462. Wang SS, Schadt EE, Wang H, et al. Identification of pathways for atherosclerosis in mice: integration of quantitative trait locus analysis and global gene expression data. Circ Res 2007;101:e11-30.

463. Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007;316:1336-41.

464. Zhu H, Poole J, Lu Y, et al. Sympathetic nervous system, genes and human essential hypertension. Curr Neurovasc Res 2005;2:303-17.

465. Leopold JA, Loscalzo J. Oxidative enzymopathies and vascular disease. Arterioscler Thromb Vasc Biol 2005;25:1332-40.

466. Olivieri F, Antonicelli R, Cardelli M, et al. Genetic polymorphisms of inflammatory cytokines and myocardial infarction in the elderly. Mech Ageing Dev 2006;127:552-9.

467. Borgel J, Sanner BM, Bittlinsky A, et al. Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels. Eur Respir J 2006;27:121-7.

468. Bostrom KB, Hedner J, Melander O, et al. Interaction between the angiotensin-converting enzyme gene insertion/deletion polymorphism and obstructive sleep apnoea as a mechanism for hypertension. J Hypertens 2007;25:779-83.

469. Lavie L, Lotan R, Hochberg I, Herer P, Lavie P, Levy AP. Haptoglobin polymorphism is a risk factor for cardiovascular disease in patients with obstructive sleep apnea syndrome. Sleep 2003;26:592-5.

470. Lin L, Finn L, Zhang J, Young T, Mignot E. Angiotensin-converting enzyme, sleep-disordered breathing, and hypertension. Am J Respir Crit Care Med 2004;170:1349-53.

471. Patel SR, Larkin EK, Mignot E, Lin L, Redline S. The association of angiotensin converting enzyme (ACE) polymorphisms with sleep apnea and hypertension. Sleep 2007;30:531-3.

472. Barcelo A, Llompart E, Barbe F, Morla M, Vila M, Agusti AG. Plasminogen activator inhibitor-I (PAI-I) polymorphisms in patients with obstructive sleep apnoea. Respir Med 2002;96:193-6.

473. Bayazit YA, Yilmaz M, Erdal E, et al. Role of nitric oxide synthase gene intron 4 and exon 7 polymorphisms in obstructive sleep apnea syndrome. Eur Arch Otorhinolaryngol 2008.

474. Diefenbach K, Kretschmer K, Bauer S, et al. Endothelin-1 gene variant lys198asn and plasma endothelin level in obstructive sleep apnea. Cardiology 2008;112:62-68.

475. Gozal D, Capdevila OS, Kheirandish-Gozal L, Crabtree VM. APOE epsilon 4 allele, cognitive dysfunction, and obstructive sleep apnea in children. Neurology 2007;69:243-9.

476. Keating BJ, Tischfield S, Murray SS, et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS ONE 2008;3:e3583.

477. Maresso K, Broeckel U. Genotyping platforms for mass-throughput genotyping with SNPs, including human genome-wide scans. Adv Genet 2008;60:107-39.

478. Morton NE. Into the post-HapMap era. Adv Genet 2008;60:727-42.

479. Uchiyama M, Ishibashi K, Enomoto T, et al. Twenty-four hour profiles of four hormones under constant routine. Psychiatry Clin Neurosci 1998;52:241-3.

480. Wyatt JK, Ritz-De Cecco A, Czeisler CA, Dijk DJ. Circadian temperature and melatonin rhythms, sleep, and neurobehavioral function in humans living on a 20-h day. Am J Physiol 1999;277:R1152-63.

481. Gilbert SS, van den Heuvel CJ, Ferguson SA, Dawson D. Thermoregulation as a sleep signalling system. Sleep Med Rev 2004;8:81-93.

482. Rasch B, Dodt C, Molle M, Born J. Sleep-stage-specific regulation of plasma catecholamine concentration. Psychoneuroendocrinology 2007;32:884-91.

483. Mendez M, Bianchi AM, Villantieri O, Cerutti S. Time-varying analysis of the heart rate variability during REM and non REM sleep stages. Conf Proc IEEE Eng Med Biol Soc 2006;1:3576-9.

484. Bach V, Telliez F, Libert JP. The interaction between sleep and thermoregulation in adults and neonates. Sleep Med Rev 2002;6:481-92.

485. Issa FG, Sullivan CE. The immediate effects of nasal continuous positive airway pressure treatment on sleep pattern in patients with obstructive sleep apnea syndrome. Electroencephalogr Clin Neurophysiol 1986;63:10-7.

486. Loredo JS, Ancoli-Israel S, Kim EJ, Lim WJ, Dimsdale JE. Effect of continuous positive airway pressure versus supplemental oxygen on sleep quality in obstructive sleep apnea: a placebo-CPAP-controlled study. Sleep 2006;29:564-71.

487. Aldrich M, Eiser A, Lee M, Shipley JE. Effects of continuous

positive airway pressure on phasic events of REM sleep in patients with obstructive sleep apnea. Sleep 1989;12:413-9.

488. Cahan C, Decker MJ, Arnold JL, Goldwasser E, Strohl KP. Erythropoietin levels with treatment of obstructive sleep apnea. J Appl Physiol 1995;79:1278-85.

489. Hashimoto S, Morohoshi K, Suzuki T, Matsushima K. Lipopolysaccharide-inducible gene expression profile in human monocytes. Scand J Infect Dis 2003;35:619-27.

490. Moore DF, Li H, Jeffries N, et al. Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation 2005;111:212-21.

491. Tanner MA, Berk LS, Felten DL, Blidy AD, Bit SL, Ruff DW. Substantial changes in gene expression level due to the storage temperature and storage duration of human whole blood. Clin Lab Haematol 2002;24:337-41.

492. Rainen L, Oelmueller U, Jurgensen S, et al. Stabilization of mRNA expression in whole blood samples. Clin Chem 2002;48:1883-90.

493. Debey S, Schoenbeck U, Hellmich M, et al. Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell types. Pharmacogenomics J 2004;4:193-207.

494. Ovstebo R, Lande K, Kierulf P, Haug KB. Quantification of relative changes in specific mRNAs from frozen whole blood - methodological considerations and clinical implications. Clin Chem Lab Med 2007;45:171-6.

495. Kagedal B, Lindqvist M, Farneback M, Lenner L, Peterson C. Failure of the PAXgene Blood RNA System to maintain mRNA stability in whole blood. Clin Chem Lab Med 2005;43:1190-2.

496. Kim SJ, Dix DJ, Thompson KE, et al. Effects of storage, RNA extraction, genechip type, and donor sex on gene expression profiling of human whole blood. Clin Chem 2007;53:1038-45.

497. Mutter GL, Zahrieh D, Liu C, et al. Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays. BMC Genomics 2004;5:88.

498. Thach DC, Lin B, Walter E, et al. Assessment of two methods for handling blood in collection tubes with RNA stabilizing agent for surveillance of gene expression profiles with high density microarrays. J Immunol Methods 2003;283:269-79.

499. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93.

500. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.

501. Hariharan R. The analysis of microarray data. Pharmacogenomics 2003;4:477-97.

502. Mantini D, Petrucci F, Pieragostino D, et al. LIMPIC: a computational method for the separation of protein MALDI-TOF-MS signals from noise. BMC Bioinformatics 2007;8:101.

503. Cui X, Hwang JT, Qiu J, Blades NJ, Churchill GA. Improved statistical tests for differential gene expression by shrinking variance components estimates. Biostatistics 2005;6:59-75.

504. Kerr MK, Churchill GA. Bootstrapping cluster analysis: assessing the reliability of conclusions from microarray experiments. Proc Natl Acad Sci U S A 2001;98:8961-5.

505. Churchill GA. Fundamentals of experimental design for cDNA microarrays. Nat Genet 2002;32 Suppl:490-5.

506. Kerr MK, Churchill GA. Statistical design and the analysis of gene expression microarray data. Genet Res 2001;77:123-8.

507. Coombes KR, Morris JS, Hu J, Edmonson SR, Baggerly KA. Serum proteomics profiling--a young technology begins to mature. Nat Biotechnol 2005;23:291-2.

508. Conrads TP, Hood BL, Veenstra TD. Sampling and analytical strategies for biomarker discovery using mass spectrometry. Biotechniques 2006;40:799-805.

509. Mayr M, Zhang J, Greene AS, Gutterman D, Perloff J, Ping P. Proteomics-based development of biomarkers in cardiovascular disease: mechanistic, clinical, and therapeutic insights. Mol Cell Proteomics 2006;5:1853-64.

510. Gulcicek EE, Colangelo CM, McMurray W, et al. Proteomics and the analysis of proteomic data: an overview of current protein-profiling technologies. Curr Protoc Bioinformatics 2005;Chapter 13:Unit 13 1.

511. Lee HJ, Wark AW, Corn RM. Microarray methods for protein biomarker detection. Analyst 2008;133:975-83.

512. Tammen H, Schulte I, Hess R, et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 2005;5:3414-22.

513. Soultan Z, Wadowski S, Rao M, Kravath RE. Effect of treating obstructive sleep apnea by tonsillectomy and/or adenoidectomy on obesity in children. Arch Pediatr Adolesc Med 1999;153:33-7.

514. Berliner JA, Zimman A. Future of toxicology--lipidomics, an important emerging area for toxicologists: focus on lipid oxidation products. Chem Res Toxicol 2007;20:849-53.

515. German JB, Gillies LA, Smilowitz JT, Zivkovic AM, Watkins SM. Lipidomics and lipid profiling in metabolomics. Curr Opin Lipidol 2007;18:66-71.

516. Wiest MM, Watkins SM. Biomarker discovery using high-dimensional lipid analysis. Curr Opin Lipidol 2007;18:181-6.

517. Maher AD, Zirah SF, Holmes E, Nicholson JK. Experimental and analytical variation in human urine in 1H NMR spectroscopy-based metabolic phenotyping studies. Anal Chem 2007;79:5204-11.

518. Wilson ID, Plumb R, Granger J, Major H, Williams R, Lenz EM. HPLC-MS-based methods for the study of metabonomics. J Chromatogr B Analyt Technol Biomed Life Sci 2005;817:67-76.

519. Su X, Han X, Mancuso DJ, Abendschein DR, Gross RW. Accumulation of long-chain acylcarnitine and 3-hydroxy acylcarnitine molecular species in diabetic myocardium: identification of alterations in mitochondrial fatty acid processing in diabetic myocardium by shotgun lipidomics. Biochemistry 2005;44:5234-45.

520. Brindle JT, Antti H, Holmes E, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 2002;8:1439-44.

521. Patel C, Ghanim H, Ravishankar S, et al. Prolonged reactive oxygen species generation and nuclear factor-kappaB activation after a high-fat, high-carbohydrate meal in the obese. J Clin Endocrinol Metab 2007;92:4476-9.

522. Ulrich C, Heine GH, Garcia P, et al. Increased expression of monocytic angiotensin-converting enzyme in dialysis patients with cardiovascular disease. Nephrol Dial Transplant 2006;21:1596-602.

523. Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006;116:115-24.

524. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115-26.

525. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.

526. Dyugovskaya L, Lavie P, Lavie L. Phenotypic and functional characterization of blood gammadelta T cells in sleep apnea. Am J Respir Crit Care Med 2003;168:242-9.

527. Dyugovskaya L, Lavie P, Hirsh M, Lavie L. Activated CD8+ T-lymphocytes in obstructive sleep apnoea. Eur Respir J 2005;25:820-8.

528. Kontogianni K, Messini-Nikolaki N, Christou K, Gourgoulianis K, Tsilimigaki S, Piperakis SM. DNA damage and repair capacity in lymphocytes from obstructive sleep apnea patients. Environ Mol Mutagen 2007;48:722-7.